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ABSTRACT 
Methylxanthines have been shown to be promising respiratory stimulants in 
newborns suffering from recurrent apnea. The respiratory stimulant effects of 
methylxanthines are most likely due to their antagonism of adenosine receptors. These 
drugs have been shown to stimulate respiration in newborn rats in doses in excess of 10 
mg/kg body weight. Structure-activity studies have shown that methylxanthines not only 
differ in the antagonism of A1 and Az adenosine receptors but also, as a consequence of 
their different chemical structures, differ in potency as respiratory stimulants. To assess 
this, two potent Ai adenosine receptor antagonists, 8-cyclopentyl-1,3-dipropylxanthine 
(DPCPX) and 8-cyclopentyltheophylline (CPT) were compared in relation to respiratory 
response in 4 -to 7-day-old rats using a body plethysmograph. DPCPX and CPT were 
administered in dosages of l 0, 20, 40, 80, 160, 320, and 640 µg/kg body weight. 
Respiratory recordings were analyzed every 5 minutes for 60 minutes for minute 
ventilation (VE), respiratory rate (f), tidal volume (VT), and mean inspiratory flow (MIF). 
Our hypotheses were that l) both DPCPX and CPTwill stimulate respiration compared 
to saline treated rats, 2) there will be a dose-response relationship between DPCPX/CPT 
treatment and respiratory stimulation and 3) that DPCPX will be more potent than CPT 
as a respiratory stimulant based on its higher affinity for A1 adenosine receptors. As 
predicted, DPCPX and CPT stimulated respiration compared to saline treated rats. 
Overall, DPCPX exhibited greater respiratory stimulation than CPT in terms of VE, f, and 
MIF mean percent change, in the dosage range of 80-320 µg/kg. This along with the fact 
that unlike DPCPX, CPT shows no significant dosage-response relationship, suggests 
that DPCPX is a more potent respiratory stimulant. 
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CHAPTER 1: INTRODUCTION 
Sleep-related breathing disorders (SRBD) are highly prevalent conditions that can 
be disastrous if not recognized and treated. There are many different types of SRBD's 
affecting both adults and children. These include, but are not limited to snoring, 
insomnia, hypersomnia, sleepwalking, narcolepsy, upper airway resistance syndrome 
(UARS), central alveolar hypoventilation syndrome (CAHS), sudden infant death 
syndrome, hypopnea, Cheyne-Stokes respiration, sleep apnea, and neonatal apnea (also 
frequently referred to or compared with apnea of prematurity) (Brouillette et al. 1990). 
SRBD's affect millions of individuals around the world and are often causes of morbidity 
and mortality. 
One of the most common types of sleep disorders is sleep apnea. Many scientist 
and sleep researchers are concerned with the rising increase of reported cases of adults 
and children with sleep apnea. In fact, among adults, sleep apnea is even more common 
than asthma. In the United States for instance, approximately 12 million people (~3%-
7%) between the ages of 30 and 60 years have obstructive sleep apnea (OSA) (Roux et 
al. 2000). According to the 1993 Wisconsin Sleep Cohort Study it has been estimated that 
1 out of every 15 people experience some form of sleep apnea (Young et al. 2009). 
Adults who are middle-aged are often also less likely to report sleep apneic episodes with 
9% of women and 24% of men being undiagnosed. Recently this estimate has increased 
to approximately 15% of U.S. population, and is rising steadily due to the increasing 
levels of obesity found in individuals within the U.S. (Young et al. 2009). Moreover, 
neonatal apnea, a form of sleep apnea affecting most newborns and premature infants in 
their first months in life, is even more concerning. Due to the increased risk of 
developing debilitating disorders, chronic illnesses, and increased morbidity as a result of 
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these apneic episodes, treating neonatal apnea is at the forefront of sleep research. 
Scientists and researchers are scrambling for new methods and treatments to prevent, 
reduce, and ultimately find a cure for sleep apnea. 
Sleep apnea, nonetheless, is a very elusive, dynamic and complex physiological 
phenomenon that makes finding effective treatments extremely difficult. The first 
dilemma seems to be defining sleep apnea in terms of its etiology and physiology, and 
distinguishing among its various types. Generally, apnea is defined as the transient 
cessation of breathing. The word is derived from the Greek word "apnoia" which means 
''want of breath" or "without breath" (The American Heritage Dictionary of the English 
Language 2009). Sleep apnea, is defined as having apneic episodes during sleep. More 
specifically, sleep apnea is "the repetitive pauses or cessations of airflow associated with 
sleep arousal and often with oxygen desaturation" (Roux et al. 2000). 
There are three type of sleep apnea: Obstructive, central and mixed. The type of 
sleep apnea is usually diagnosed on the basis of whether it is a result of 1) an 
"obstructive event", a compromised or restricted, often completely closed upper airway, 
2) a "central event", any reduction or cessation of brain stem respiratory motor output, or 
3) a combination of both obstructive and central events (Dempsey et al. 2010). However, 
the fact that sleep apnea is divided into "central" events and "obstructive" events does 
little to clarify the causes of sleep apnea. This is because "most cyclical sleep-disordered 
breathing events are driven by anomalies in both anatomical and neurochemical control 
of upper airway and/or chest wall respiratory musculature" (Dempsey et al. 2010). Thus, 
to thoroughly understand the different types of sleep apnea it is crucial to examine the 
epidemiology, pathophysiology, diagnosis, effects of, and treatments of each type of 
sleep apnea individually. 
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Effectively diagnosing sleep apnea, especially the type of sleep apnea (e.g. 
central, mixed, obstructive) is a major problem for physicians and sleep researchers. 
Many individuals who actually suffer from some form of sleep apnea often are 
misdiagnosed with other sleep related disorders (e.g. insomnia, snoring, etc.). This occurs 
most often in women, and certain individuals who are obese, elderly, or have other 
comorbidities (e.g. heart problems, respiratory disabilities). Often the failure to 
accurately diagnose sleep apnea is the physician's fault by simply not asking relevant 
questions or by providing ineffective screening (Barnett et al. 2011 ). 
Another conflict that arises when trying to develop effective treatments for sleep 
apnea is that sleep apnea occurs in adults and both mature and premature infants. Adults 
and infants differ dramatically in terms of their physiology, which often causes a 
dichotomy between the prevalence and severity of sleep apnea among adults and infants. 
As a result, treatment strategies often differ between adults with sleep apnea and neonatal 
apnea (Erler and Paditz 2004). 
Lastly, specific treatment strategies for apnea need to take into account not only 
the different types of sleep apnea (i.e. central sleep apnea (CSA), obstructive sleep apnea 
(OSA), and mixed sleep apnea), differentiate between sleep apnea in adults and neonatal 
apnea, but also be based on a particular individual's own biology, medical history, 
physical examinations, and sleep study results. Sleep apnea treatments have included and 
currently consist of a wide range of different methods including, but not limited to: 
Continuous positive airway pressure (CPAP), tonsillectomy, oral applications, nasal 
appliances, prone positioning, oxygen therapy, orogastric feeding, kangaroo mother care, 
C02 inhalation treatment, thermoregulation, red blood cell transfusion, home monitoring, 
and various pharmacological treatments (e.g. oxygen, doxapram, acetazplamide, 
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methylxanthines, etc.) (Zhao et al. 2011). 
The devastating consequences associated with sleep apnea and neonatal apnea, 
and the fact that the number of reported cases of sleep apnea and neonatal apnea are 
increasing dramatically illustrates the importance for the advancement of sleep apnea 
research. In addition, its complex nature only further compounds the need to find 
effective treatments and cures. Treatment of neonatal apnea has become even more 
pressing. Not only are neonates more likely to suffer from apnea, be misdiagnosed, suffer 
from morbidity, and have other long-term consequences, neonates also deal with stress 
less efficiently (Brouillette et al. 1990). 
Today, one of the most progressive and promising forms of treatments (aside from 
CPAP therapy) is the use of pharmacological drugs, such as xanthine derivatives or 
methylxanthine treatment in particular (Schmidt et al. 2007). Methylxanthine treatment 
dates back to the early 1970s. The two most commonly used methylxanthines for 
treatment of apnea are caffeine (1, 3, 7-trimethylxanthine) and theophylline (1, 3-
dimethylxanthine) (Rall 1990). Methylxanthines are typically prescribed in very preterm 
infants and have been shown to reduce apnea frequency and the need for mechanical 
ventilation in the first seven days of treatment (Orozco-Gregorio et al. 2011). 
While methylxanthines such as caffeine and theophylline have a variety of similar 
pharmacological effects, the real potential for methylxanthine treatment lies within the 
dynamic chemical structure of methylxanthines. Structure-activity studies have shown 
that methylxanthines not only differ in the antagonism of Ai and Az adenosine receptors 
(receptors that help regulate sleep), but also differ in their potency as adenosine 
antagonists as a consequence of their chemical structure (Rall 1990). 
14 
-------------------·-········"-•·---------------------
Researchers today are using this knowledge to synthesize xanthine derivatives 
that may provide xanthine analogs with more flexible and potent properties. For instance, 
it has been demonstrated that substituents of alkyl groups at positions 1, 3, and 7 as well 
as the addition of aromatic, cyclohexyl and cyclopentyl groups at position 8 can 
dramatically influence the potency ofmethylxanthines (Shamim et al. 1989). More 
importantly, researchers suggest the potency of xanthine derivatives stems from their 
ability to inhibit cyclic nucleotide phosphodiesterase and antagonize the receptor actions 
of adenosine (Rall 1990). Thus, methylxanthines not only competitively inhibit the 
actions of these adenosine receptors (i.e. regulating cardiovascular and respiratory 
stimulation) but do so in accordance with its general chemical structure and their affinity 
for either A1 or A2 receptors (Shamim et al. 1989). It is also believed that efficacy may be 
highly dependent on the specific dosage range of a methylxanthine (McGilliard and 
Saeki 2002). 
One way to analyze these potential chemical and physiological properties of 
methylxanthines on respiratory stimulation is by comparing the respiratory effects of 
various chemically altered xanthine derivatives (Rall 1990). As stated earlier, to date 
there is evidence that these manipulated xanthine derivatives can differ dramatically in 
their ability to antagonize/agonize A1 and A2 adenosine receptors and as a result provide 
various physiological effects (e.g. bronchodilation, phosphodiesterase regulation, 
cardiovascular stimulation, respiratory stimulation/depression, etc.) (Rall 1990). 
Nonetheless, many of these studies are either somewhat antiquated or fail to take into a 
detailed account the variegated degree of potency of these various xanthine derivatives. 
In an attempt to resolve this, this study tested whether xanthine derivatives differ 
in their potency (as respiratory stimulants) as a result of their chemical structure. In 
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addition, this study tested whether or not there is a dose-response relationship to 
methylxanthine treatment. Specifically, this study compared the respiratory responses of 
two potent At adenosine receptor antagonists, 8-cyclopentyl-1, 3-dipropylxanthine 
(DPCPX) and 8-cyclopentyl-1, 3-dimethylxanthine ( cyclopentyltheophylline or CPn. 
Respiratory responses were analyzed using 4-to 7-day-old rats (age in which rats have 
similar physiology to preterm infants (Rigatto et al. 1975; McGilliard, 1984), and it's also 
the age in which rats have been used in previous studies (McGilliard and Saeki 2002)) 
using a body plethysmograph. Rats were used not only because are they readily 
available, easily treatable and modifiable in terms of experimentation; but they also 
demonstrate many of the attributes seen in preterm infants suffering from apnea (i.e. 
immature respiratory system, similar breathing patterns, etc.). Moreover, there are many 
related studies involving rats as subjects for the treatment of apnea. 
In the present study, DPCPX was administered in dosage increments of 10, 20, 
40, 80, 160, 320, and 640 µg/kg body weight. CPT (despite its lower A1 adenosine 
receptor potency) was administered at the same dosages. Respiratory recordings were 
evaluated every 5 minutes for 60 minutes for minute ventilation (the volume of air 
exhaled from a person's lungs in one minute; VE), respiratory rate (the number of breaths 
taken per minute; f), tidal volume (the amount of air moved into and out of the lungs 
during normal breathing; VT), and mean inspiratory flow (the average rate of air flow 
during inspiration; VTIT1), where T1 is the time of inspiration 
The hypotheses are 1) both DPCPX and CPT will increase respiration response 
compared to control treatments (i.e. saline treated rats), 2) there will be a dosage-
response relationship between DPCPX/CPT treatment and respiratory stimulation, and 3) 
DPCPX will be a more potent respiratory stimulant than CPT based on its higher affinity 
16 
for A1 adenosine receptors. 
The main objectives and goals of this study are 1) to examine the effectiveness of 
methylxanthine treatment on neonatal rats in terms of respiratory response, 2) 
demonstrate how methylxanthine structure affects its potency as an adenosine antagonist, 
3) compare two potent A1 adenosine receptor antagonists (DPCPX and CPT) on 
respiratory response as well as to previous studies involving less potent adenosine 
receptor antagonists (i.e. caffeine, theophylline), 4) compare the dosage-response 
relationship ofDPCPX and CPT in terms of respiratory response, 5) demonstrate the 
importance of how structurally manipulated methylxanthines can be used as treatment 
strategies for neonatal apnea, 6) demonstrate that VE, f, VT, and VTIT1 can be used as 
indicators of respiratory response and thus variables to evaluate the effectiveness of 
methylxanthine treatment, 7) evaluate the overall effectiveness of this experimental 
design for future respiratory studies-specifically for the treatment of neonatal apnea, and 
lastly 8) provide a general understanding and awareness of sleep apnea and neonatal 
apnea. 
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CHAPTER 2: LITERATURE REVIEW 
I. History 
Even though there were physiological implications of sleep apnea as early as the 
19th Century, much of what we know about sleep apnea was not accurately elucidated 
until the early 1970s. In the 1850s and the 1870s British physicians reportedly identified 
obstructed apneas as "fruitless contractions of the inspiratory and expiratory muscles 
against glottic obstruction with accompanying cyanosis during sleep" (Dempsey et al. 
2010). In the early 19th Century British physician Hunter and Irish physicians Cheyne 
and Stokes noticed periodic breathing in patients with heart failure. Near the end of the 
19th century, several cases of obese individuals with extreme conditions of daytime 
sleepiness were described and diagnosed as having "Pickwickian syndrome" after the 
Charles Dickens "Fat Boy Joe" in the Pickwick Papers in 1837. Near the tum of the 20th 
Century British physiologists John Scott Haldane, C.G. Douglas, and Mabel Fitzgerald 
witnessed periodic breathing in otherwise healthy subjects sleeping in the hypoxia of 
high altitudes. It was not until the 1950s that an association between obesity and the 
control of breathing was made. In these obese subjects daytime C02 retention was 
observed without any presence or indication of significant lung disease. At first, this 
daytime sleepiness accompanied by respiratory failure was ascribed to being a result of 
"C02 poisoning". There was no association between daytime sleepiness and respiratory 
failure due to sleep disorders. It wasn't until the early 1960s that the descriptions of sleep 
effects on ventilation and ventilatory stability in health were described as seen in 
"Bulow's comprehensive studies". By the mid 1960s, Gastaut et al. provided the first link 
between obesity, sleep-induced airway obstruction, sleep fragmentation, and daytime 
sleepiness by recognizing OSA in obese subjects as intermittent airway obstruction with 
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frequent arousals (Dempsey et al. 2010). From the mid 1970s to the early 1980s 
physiological research in the field of sleep and breathing was gaining momentum as 
exemplified by several detailed studies: "l) the sleep effects on brain stem respiratory 
neuronal activity in the unanaesthetized, chronically instrumented cat, 2) a 
neuromuscular reflex mechanism maintaining extrathoracic airway patency in the rabbit, 
3) sleep effects on reflex control of breathing in the dog and identification of a sensitive 
C02-induced apneic threshold in sleeping humans, 4) description of anatomical and 
neurophysiological determinants of upper airway occlusion in the sleeping human, which 
provided a unifying (balance of forces) concept of obstructive sleep apnea (OSA) 
pathogenesis, and 5) the landmark introduction of continuous nasal pressure (CPAP) 
application as noninvasive treatment for obstructive sleep apnea" (Bradley 2008). In the 
mid 1990s, the first population sleep study (the Wisconsin Sleep Cohort) was conducted 
and described the remarkable prevalence of sleep apnea or sleep disordered breathing on 
public health (Young et al. 2009). Since then research concerning sleep apnea has 
dramatically increased (Young et al. 2009). The understanding of sleep apnea in terms of 
its prevalence, causes, types, consequences, and various responses to different treatment 
strategies has provided the impetus for researchers and scientists to find more effective 
treatments and preventive care. 
II. Types of Sleep Apnea 
A. Obstructive Sleep Apnea 
OSA is the most common form of sleep apnea affecting approximately 4% of 
men and 2% of women or nearly 18 million Americans (Patil et al. 2007). OSA is defined 
as the recurrent cessation of breathing caused by upper airway obstructions (fig. 1) 
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(Hollenstein 2010). These obstructions are typically caused by the throat and tongue 
muscles relaxing and as a consequence the soft tissue of the back of throat collapses 
blocking the upper airway ("Obstructive Sleep Apnea" 2008). Recognizing the 
pathogenesis, signs and symptoms, and accurately diagnosing OSA is key to developing 
effective preventive strategies (e.g. screening) and therapeutic measures (e.g. treatments) 
to combat this disorder (Patil et al. 2007). 
hin Nl . e 
I ~kcd =iinvav 
Figure 1: Diagram illustrating Obstructive Sleep Apnea (OSA) (Hollenstein 2010). 
There are three different types of OSA: mild, moderate, and severe obstructive 
sleep apnea. These different types of OSA are determined by the apnea-hypopnea index 
(AHI) and are categorized in terms of sleepiness in relation to attention span. Mild OSA 
(AHI between 5-15) involves involuntary sleepiness in situations which require little to 
no attention (e.g. watching T.V., reading), moderate OSA (AHI between 15-30) is 
involuntary sleepiness in situations that require some attention (e.g. meetings, 
conferences), and severe OSA (AHI above 30) is involuntary sleepiness in situations that 
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require more active attention (e.g. talking, driving) ("Obstructive Sleep Apnea" 2008). 
Obstruction of the upper airway or upper respiratory tract can be either complete 
or incomplete. Incomplete obstructions of the upper respiratory tract are called 
obstructive hypopnea or obstructive hypoventilation, while complete obstruction of the 
upper respiratory tract is called obstructive sleep apnea. This delineation is important in 
that children and adults with obstructions are affected differently in terms of whether this 
obstruction is incomplete or complete. Children are more likely to have incomplete 
obstructions (due to the immaturity of the respiratory tract) while adults are more likely 
have complete obstructions and are diagnosed as having OSA (Erler and Paditz 2004). 
This is primarily due to the fact that while the fundamental pathophysiology of the upper 
airway obstruction in OSA in children and adults is somewhat similar there are also 
critical differences. 
In addition to causing pauses in breathing, these obstructions can also reduce (up 
to 40% or more) blood oxygen levels. These periodic pauses in breathing not only cause 
reduction in ventilation and episodic oxyhemogloblin desaturations but as a consequence 
of this, can also lead to daytime hypersomnolence, neurocognitive dysfunction, 
cardiovascular disease (e.g. heart failure, hypertension, stroke, myocardial infarction), 
metabolic dysfunction, respiratory failure, and cor pulmonale (Erler and Paditz 2004). 
Moreover, OSA in children can be dangerous in that it can substantially interfere with a 
child's growth and development (e.g. neuropsychological problems, cognitive 
disabilities) (Erler and Paditz 2004). Many individuals are unaware that they may have 
OSA. Left untreated, not only can OSA lead to numerous secondary diseases but it also 
increases the risk of mortality. 
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It should also be noted that respiration during sleep is much more sensitive to 
disturbances as opposed to respiration in an awakened state. Muscle tone is diminished 
drastically during the non-rapid eye movement (NREM) stages of sleep and is literally 
undetectable during rapid eye movement (REM) stages of sleep. Moreover, intercostal 
musculature is inhibited during REM sleep, drastically reducing any chances of 
compensation for increased resistance (i.e. the respiration response to C02) in the 
respiratory tract. One of the largest differences in the pathophysiology of OSA between 
children and adults is the variance in the quantity of sleep between the two groups. 
Babies and children are in REM sleep 40-80% of their time while adults are only in REM 
sleep 10-30% of their time. This difference results in dissimilar sensitivities to increased 
anatomical or functional reductions in the upper respiratory tract (Erler and Paditz 2004). 
The major risk factors for OSA are obesity (body mass index of 30 or above), 
being male, postmenopausal women, and old age (Patil et al. 2007). Other risk factors 
include: men and women with large necks (17 inches or more for men; 16 inches or more 
for women), ethnic minorities, people with abnormalities in the head and neck, adults and 
children with Down Syndrome, children with large tonsils and adenoids, having genetic 
predisposition to OSA, individuals with endocrine disorders (e.g. acromegaly, 
hyperthyroidism), smokers, and those suffering from nocturnal nasal congestion (e.g. 
rhinitis) ("Obstructive Sleep Apnea" 2008). 
B. Central Sleep Apnea 
Central sleep apnea (CSA) is the second most common type of sleep apnea and 
differs from OSA in several ways. First, CSA is defined by the cessation of airflow 
without respiratory effort, as opposed to OSA which is with respiratory effort (Malhotra 
and Owens 2010). CSA occurs due to complete or partial reductions in central neural 
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outflow to the respiratory muscles during sleep. This leads to complete or partial 
cessation of airflow for at least I 0 seconds. There are at least five types of CSA: sleep 
transition apnea, narcotic-induced central apnea, Cheyne-Stokes breathing (CSB), 
complex sleep apnea, and idiopathic central apnea. Not only do these types of CSA differ 
in terms of their mechanisms but also in terms of treatment (fig. 2). 
Type of Central Apnea Mechanism Treatment 
Sleep transition apnea Ventilatory response to arousal drives Pm, below apnea threshold Reassurance 
Sleep hygiene 
Hypnotic therapy 
Oxygen 
Narcotic-induced central ap- Unclear, suppressed output from respiratory pattern generator Reduce narcotic dose 
nea Consider advanced PAP de-
vice 
Cheyne-Stokes breathing High loop gain from extravascular lung water and robust chemorespon- Optimize medical therapy 
siveness Consider PAP 
Complex sleep apnea CPAP reduces upper-airway resistance, improving the efficiency of Reassurance 
CO, excretion Expectant management 
Idiopathic central apnea Unknown Acetazolamide 
Consider bi-level PAP 
Figure 2: Forms of Central SleepApnea (CSA) (Malhotra and Owens 2010). 
Sleep transition apnea is largely defined as "fluctuations in ventilation that occur 
in otherwise normal individuals during the transition from wake to sleep" (Malhotra and 
Owens 2010). It is characterized by the arousal from sleep, which is the augmentation of 
ventilation particularly after waking up. In normal individuals PaC02 (partial pressure of 
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carbon dioxide in arterial blood) = 40 mm Hg during wakefulness and P aC02 = 45 mm 
Hg during NREM sleep. When these individuals normally wake up from sleep they 
hyperventilate and drive down their PaC02 levels below their normal awake PaC02-level. 
If this rise in ventilation yields a PaC02 below the apnea threshold, then cessation of 
breathing is likely to occur. Treatment includes reassurance, sleep hygiene (e.g. normal 
sleep and wake cycles, napping), hypnotic therapy and oxygen treatments (Malhotra and 
Owens 20 I 0). 
Narcotic-induced sleep apnea involves the presence of central sleep apnea as a 
result of narcotic therapy. Narcotic analgesics (opiates) are known to depress respiration. 
Narcotic-induced sleep apnea occurs primarily in patients who are on chronic narcotic 
regimes because of chronic pain or drug abuse. It is estimated that approximately 10-50% 
of chronic narcotic users have some type of central apnea. Treatment should first be 
focused on reducing the narcotic dose by supplementing or replacing with certain non-
narcotic analgesic drugs, such as gabapentin. Advanced PAP devices may also be used as 
a treatment strategy (Malhotra and Owens 20 I 0). 
CSB or Cheyne-Stokes respiration is a "form of periodic breathing in which the 
ventilatory period is characterized by prolonged waxing/waning pattern of tidal volume 
followed by central apnea or hypopnea" (Bradley and Dai 2008). CSB is one of the most 
well studied forms of CSA to date. CSB is mostly seen in patients with chronic heart 
failure. In fact, it has been estimated that 30-50% of all patients with left-ventricular 
systolic dysfunction have CSB. Contrary to most medical studies where CPAP therapy 
for CSA is marginal and largely controversial, CPAP therapy for individuals with CSA as 
well as chronic heart failure has shown remarkable improvements. Nonetheless, while 
CPAP therapy for individuals with chronic heart failure has shown to improve both 
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breathing and in addition left-ventricular function, there may be more specific and thus 
more beneficial treatments available (Malhotra and Owens 2010). 
Complex apnea is for the most part defined as "the development of central apnea 
in individuals with obstructive sleep apnea when initially exposed to CPAP" (Malhotra 
and Owens 2010). However, with ongoing CPAP therapy the conditions attributed with 
complex apnea usually diminish. In roughly 1-2% of cases complex apnea is still present 
and different treatment options may be more effective. This includes hypnotic therapy, 
oxygen therapy, and acetazolamide (Malhotra and Owens 2010). 
C. Mixed Sleep Apnea 
Mixed sleep apnea is defined as having the properties similar to both OSA and 
CSA. More specifically, mixed apnea is CSA that develops an obstructive apnea. Thus, in 
a sense mixed apnea is similar to OSA in terms of the manner in which they occur; 
specifically, the sleep-related decrease of pharyngeal airway dilation (Bhatia 2000). 
Moreover, apneas that last longer than I 0 seconds typically can be classified as mixed 
apneas (Dorion and Praud 2003). Mixed apneas, are common in individuals with 
"chronic heart failure for significant portions of sleep time. This is particularly true in 
those patients who are obese and/or with a history of snoring" (Dempsey et al. 20 I 0). 
Nonetheless, mixed apneas are the least common form of sleep apnea among the general 
population, and in fact more prevalent in premature infants. In premature infants the 
primary form of sleep apnea consists of apneas that are about 65% central and 35% 
obstructive in origin (Bhatia 2000). Individuals are "considered to have mixed apnea if 
the AHi is greater than or equal to 5 and more than 50% of the respiratory disturbances 
were as a result of mixed apneas" (Brown et al. 2007). 
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D. Idiopathic Apnea 
Idiopathic sleep apnea is defined as sleep apnea in which there is no known or 
provable cause. Idiopathic sleep apnea is diagnosed when medical professionals cannot 
classify the apnea as central apnea, obstructive apnea, or mixed apnea. This is most often 
seen in patients when there are several underlying causes to their apnea. However, due to 
their unidentified nature they cannot necessarily be classified as a mixed apnea. As a 
result there is not much literature pertaining to idiopathic sleep apnea. Malhotra and 
Owens (2010), suggest that idiopathic sleep apnea is extremely rare and most likely the 
result of polysomnography (PSG) phenomena rather than clinical phenomena. To date 
treatment for idiopathic sleep apnea includes acetazolamide and Bi-level PAP therapy. 
III. Neonatal Apnea 
Neonatal apnea, although similar in many ways, can differ from sleep apnea on 
many different levels. Thus distinguishing sleep apnea from neonatal apnea in terms of 
definition, etiology, physiology, consequences, and preventive care can be beneficial 
when researching and developing different treatment strategies. 
A. What is NeonatalApnea? 
All babies have recurrent pauses in breathing that typically last anywhere 
between six and ten seconds. This occurs whether the newborn is full-term or premature 
(Brouillette et al. 1990). Periodic breathing is defined as "three or more respiratory 
pauses of more than three seconds in duration with less than 20 seconds in respiration 
between pauses" (Brouillette et al. 1990). This is considered clinically significant if these 
periodic breathing episodes last 20 seconds or longer or are associated with hypoxia, 
bradycardia, cyanosis or pallor. Like sleep apnea in adults, there are three forms of apnea 
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in neonates as well: central, obstructive, or mixed (periodic breathing as result of both 
central and obstructive pathology). In premature neonates most apneic episodes are 
mixed (Brouillette et al. 1990). 
B. Prevalence of Neonatal Apnea 
Apneic episodes typically tend to decrease with age, likewise they are more 
common in small preterm infants and increase with decreasing gestational age 
(Brouillette et al. 1990). Approximately 85% of infants who are born at less than 34 
weeks of gestation suffer from apnea. The incidence is even higher in extremely preterm 
infants and almost universal in infants weighing less than 1 OOO g at birth (Orozco-
Gregorio et al. 2011). In fact, apnea of prematurity is one of the most frequently 
diagnosed conditions in neonate intensive care units (Orozco-Gregorio et al. 2011). 
Generally, apnea of prematurity (AOP) is defined as the cessation of breathing 
that lasts for more than 15 seconds and is accompanied by hypoxia or bradycardia 
(Schmidt et al. 2006). However, more recently the most widely used clinical definition of 
AOP is pauses of breathing for more than 15-20 seconds, or accompanied by oxygen 
desaturation (Sp02:S80% for ?:4 s) and bradycardia (heart rate<2/3 of baseline for ?:4 s), 
in infants born less than 37 weeks of gestation (Zhao et al. 2011). 
C. Causes of Neonatal Apnea 
Aside from determining whether the etiology of apnea is central, obstructive, or 
mixed, in most cases the exact pathological cause of neonatal apnea is unknown 
(Brouillette et al. 1990; Zhao et al. 2011 ). It is widely believed that neonatal apnea is a 
consequence of an immature respiratory drive (e.g. immaturity of the rib cage, 
diaphragm, and respiratory muscles), and an imbalance in the sympathetic and 
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parasympathetic outputs (i.e. vulnerability of the ventral surface of the medulla and 
adjacent areas of the brainstem to inhibitory mechanisms) (Brouillette et al. 1990; Bhatt-
Mehta and Schumacher 2003 ; Orozco-Gregorio et al. 2011 ). According to Brouillette et 
al. (1990) the newborn infant suffers from complications arising from immaturity of 
brainstem respiratory centers. Moreover, in the infant the intercostal muscles are weak 
and breathing largely depends on diaphragm contractions. However, in an infant the chest 
tends to collapse and make such contractions inefficient. The fact that infants have a 
narrow upper airway, and a large epiglottis, as well as display neck flexion may result in 
an infant's tendency for preferential nasal breathing and obstruct the upper airway (fig. 3; 
illustration of narrow airway) . 
Trachea -:--~-:::;:31>---4--.!... (windpipe) 
Bronchiokt 
(airway) 
Figure 3: Respiratory System oflnfant (Mount Nittany 2009). 
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However, various other factors including upper airway obstructions (e.g. narrow upper 
airway, large epiglottis, neck flexion), certain behavioral states (e.g. feeding, exertional 
breathing pattern or agitation, hiccups), reflexes (e.g. airway stimulation from suction 
catheters, gastroesophageal reflex and regurgitation), seizures, intraventricular 
hemorrhaging, central nervous system (CNS) malformations, certain infections (e.g. 
bacterial or viral sepsis, meningitis, pneumonia), metabolic disorders (e.g. hypoglycemia, 
hypoxemia, hypocapnia, thermal stress), anemia, depressant drugs (e.g. narcotics, 
barbiturates, other depressants), and certain environmental stimulants can also cause 
and/or exacerbate neonatal apneic episodes (Brouillette et al. 1990; Bhatt-Mehta and 
Schumacher 2003; Zhao et al. 2011). 
The exact etiology of apnea in full-term infants as opposed to infants born 
prematurely may or may not differ. Typically premature infants are most likely to 
experience AOP as a result of an extremely immature CNS and autonomic nervous 
system (ANS) (Brouillette et al. 1990; Bhatt-Mehta and Schumacher 2003; Bozzetti et al. 
2010). In full-term infants apnea is often the result of seizures, anatomical obstruction, 
infection, and reflux. However, in many cases the etiology of apnea in full-term infants is 
suggested to be due to an immature CNS-similar to premature infants (Bozzetti et al. 
2010). 
IV. Treatment Strategies for Sleep Apnea & Neonatal Apnea 
A. Treatments for Sleep Apnea 
Treatment for sleep apnea is tailored to the individual's medical history, 
polysomnography results, and physical examination. Treatment methods may also differ 
significantly between children and adults as well as differ in individuals diagnosed with 
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sleep apnea as opposed to neonatal apnea or AOP. 
1. Positive airway pressure (PAP) is currently the standard treatment used for 
sleep apnea (Dhand 2010). The form of PAP therapy most commonly used by adults 
today is continuous positive airway pressure (CPAP) (Erler and Paditz 2004). 
CPAP was first introduced as a treatment for sleep apnea in 1981. CPAP requires 
the air pressure to be constant between inspiration and expiration in order to keep the 
collapsed respiratory tract open (Antonescu-Turcu et al. 2010). It also provides greater 
expiratory lung volume and as a consequence increases oxygen stores and improves 
tracheal traction to increase upper airway integrity and lower cardiac load. Unfortunately, 
the use of CPAP therapy is most effective for treating OSA, and not necessarily other 
apneas such as central and mixed apneas that may require alternative ventilatory 
treatments (Brown et al. 2007). 
The efficacy of CPAP treatment for children and adolescents has yet to be 
analyzed. There is also no information concerning the adverse effects of CPAP therapy 
with prolonged use in children. There are some concerns that CPAP use can cause 
midfacial hypoplasia. Moreover, children and adolescents often recover naturally from 
sleep apnea as they grow, so annual PSG testing is critical if CPAP therapy is a 
consideration. Correct CPAP pressure, which is vital to establishing stable sleep patterns, 
is often miscalculated or the device is misassembled. Leaks may lead to a significant 
simultaneous decrease in pressure and increase of nasal flow causing severe disturbances 
in the depth of sleep (Erler and Paditz 2004). Moreover, while CPAP therapy for 
individuals with both CSA and chronic heart failure has been shown to be beneficial, 
more specific treatments such as the measurement of serum brain natiuretic peptide 
levels and cardiac resynchronization therapy may provide more reliable forms of 
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treatment (Malhotra and Owens 2010). 
2. It is important to note that ifthere are organic causes or physical abnormalities 
(e.g. adenoidal vegetation, tonsillar hypertrophy) causing sleep apnea, often the most 
practical form of treatment, especially in a child, is an adenotomy, tonsillectomy, 
tonsillotomy, and or adenotom;illectomy. However, a PSG test should be carried out to 
determine if an individual has sleep apnea before any of the previously mentioned 
procedures are undertaken. While these treatments have been shown to reduce and 
sometimes eliminate the occurrence of sleep apnea they are not necessarily permanent 
solutions and can also have adverse effects on the individual (Erler and Paditz 2004). 
3. Oral appliances are often used for treatment of sleep apnea in individuals who 
prefer them to CPAP, or cannot meet the guidelines for treatment with CPAP therapy. 
Oral appliances are effective in that they help to stabilize or reposition the lower jaw, 
tongue, soft palate or uvula providing an open and unobstructed airway. According to 
Goessler et al. (2007) "Soft palate implants may significantly reduce the number of 
obstructive events in patients with mild to moderate OSA". 
4. Nasal applications include corticosteroids and fluticasone proportionate nasal 
sprays. While the efficacy of these treatments has not been adequately substantiated, 
these treatments have been shown to reduce the frequency of mixed and obstructive sleep 
apnea (Erler and Paditz 2004). 
5. Sometimes simply changing one's lifestyle may be the most effective treatment 
for sleep apnea. For instance, such behavioral changes as losing weight and sleeping on 
one's side as opposed to one's back have been shown to reduce the frequency of sleep 
apnea occurrences and in some cases provide a permanent solution to sleep apnea. Also, 
avoiding alcohol consumption, tobacco use, and sleeping pills, which are all known to 
31 
cause the airway to collapse and prolong apneic episodes, can help alleviate conditions 
associated with sleep apnea. While over-the-counter remedies such as nasal drips, 
internal nasal dilators, and nasal lubricants may provide temporary relief to certain 
aspects of sleep apnea (e.g. snoring), there is no solid evidence that they actually treat 
sleep apnea. In fact, they may exacerbate the problem by masking one the most crucial 
indications of sleep apnea-snoring (Erler and Paditz 2004). 
6. In cases where noninvasive therapies such as CPAP, oral appliances, and nasal 
applications are ineffective or otherwise not viable, surgery is often used as treatment. 
Plastic surgery or reconstructive surgery is most effective for individuals with physical 
abnormalities or deformities (e.g. midfacial hypoplasia and/or micro-retrognathy, 
hydrocephalus with Arnold-Chiari malformation) (Erler and Paditz 2004). One of the 
most common surgical methods is uvulopalatopharyngoplasty (UPPP), which reduces the 
size of the soft palate and may involve the removal of the tonsils or uvula. Laser-assisted 
uvulopalatoplasty or radiofrequency tissue ablations are procedures that increase the 
dimension of the upper airway by removing soft tissues (e.g. soft palate, uvula, tongue, 
and tonsils) that would otherwise cause obstructions (Goessler et al. 2007). Also, in 
severe or emergency cases of obstructive sleep apnea both a tracheotomy and the 
insertion of a nasopharyngeal tube is required (Erler and Paditz 2004) 
7. Other various treatments include (but not limited to): oxygen therapy, hypnotic 
therapy, acetazplamide, and Bi-level PAP therapy. 
B. Treatments for Neonatal Apnea 
Inadequately or ineffectively treated neonatal apnea has the potential for 
devastating long-term consequences, including chronic illness, mental and physical 
impairments, and even death. Moreover, treatment is often difficult due to the inability to 
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effectively diagnose the type of apnea or its etiology and/or severity (Brouillette et al. 
1990). 
It is important to monitor both premature and full-term infants experiencing 
apneic episodes or breathing-related conditions that might lead to neonatal apnea or AOP. 
Often, guided by cardiorespiratory monitoring, physical stimulation, medication, or 
assisted ventilatory support is used until respiration is mature (Brouillette et al. 1990). 
1. Physical stimulation involves the tactile or auditory (e.g. nudging the infants 
foot or hitting the top of the isolette), or proprioceptive (e.g. water bed) rousing of the 
infant from apneic episodes. 
2. Assisted ventilatory support is typically provided by CPAP. As mentioned 
earlier, CPAP works by distending the upper airway, thereby preventing obstruction. This 
is particularly effective for infants suffering from OSA, as well as adults suffering from 
sleep apnea. In premature infants CPAP can be effective, but it is often intolerable in 
older children. 
3. Evaluation in a sleep laboratory is often beneficial especially prior to treatment. 
After examining the sleep history of the infant, typically a growth-curve determination, is 
performed, and a lateral neck x-ray at soft-tissue setting to look for any abnormality in 
the airway or anatomic causes for obstruction is conducted. An ECG or echocardiogram 
helps to rule out cor pulmonale. To evaluate the number of apneic episodes, the severity 
of partial airway obstruction, and the degree ofhypercapnia and/or hypoxemia 
polygraphic monitoring is often performed during natural sleep. Typically the method of 
treatment for OSA is tonsillectomy and adenoidectomy. Tracheostomy, although 
effective, is only necessary in extreme cases (Brouillette et al. 1990). 
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4. Home monitoring, although in a sense convenient, and assuring to the parents, 
should be considered only after all the costs and benefits have been analyzed. To some 
parents it can be a source of stress. The extra demands and responsibilities of caring for a 
monitored infant, the cost, the difficulty in finding child care, technological weaknesses 
(e.g. ECG motion artifacts, failure to accurately identify OSA, false alarms) and 
equipment failures are some of the downsides to home monitoring (Brouillette et al. 
1990). 
C. Treatments for Apnea of Prematurity 
As with neonatal apnea, to accurately and effectively treat AOP it is important to 
not only know the etiology and duration, but also the sequence by which the events 
occur. For instance, episodes of apnea that are a result of an underlying cause, or 
secondary apnea, are best treated by targeting the underlying cause (e.g. infection, patent 
ductus arteriosus, seizures, maternal or neonatal medication intoxication, gastroesphageal 
reflux (GER)). Treatment of symptomatic idiopathic apnea can be much more difficult. 
Usually both pharmacologic and nonpharmacologic (e.g. temperature, oxygen 
stimulation) treatment approaches are necessary. Most, if not all, treatments have adverse 
side effects and it is important to weigh both the risks and benefits of any treatment 
(Bhatt-Mehta and Schumacher 2003). The pathogenesis and long-term 
neurodevelopmental effects of AOP are poorly understood making AOP treatment 
difficult (Zhao et al. 2011 ). 
AOP treatments are similar to the treatments available for neonatal apnea but 
may often include such treatments as prone positioning, nasal intermittent positive 
pressure ventilation (NIPPV), Kangaroo mother care, C02 inhalation, orogastric feeding 
tube placements, and red blood cell transfusions, although the latter two are rarely used 
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(Zhao et al. 2011 ). 
1. Prone positioning is typically one of the first treatment methods used for AOP. 
Extension of the neck (i.e. neck flexion) 15° from the prone position is referred to as the 
head elevated tilt position. While the head elevated tilt position has been found to 
decrease episodes of oxygen desaturation by up to 48.5%, it does not work well in 
combination with other pharmacological therapies (e.g. methylxanthine treatment) (Zhao 
et al. 2011). 
2. "CPAP delivers a continuous distending pressure via the infant's pharynx to 
the airways to prevent both pharyngeal collapse and alveolar atelectasis" (Zhao et al. 
2011 ).As a result CPAP therapy can enhance functional residue capacity, ease the process 
of breathing, improve oxygenation and decrease bradycardia. CPAP is most effective for 
infants suffering from obstructive apnea, and has little efficacy with central apnea. An 
extension of CPAP therapy is the NIPPV. NIPPV has been proven to prevent extubation 
failure and for the treatment of AOP. Moreover, using a technique that combines CPAP 
and NIPPV treatments, variable-flow nasal continuous positive airway pressure (NCPAP) 
has been proven to even more effective than NIPPV (Zhao et al. 2011 ). 
3. Kangaroo mother care, also known as skin-to-skin care, for premature infants is 
still highly controversial for the prevention and treatment of AOP. While skin-to-skin 
care has been shown to produce calming effects on premature infants clinical status and 
vital signs, studies show that its effectiveness at treating AOP are mixed and further 
studies are needed (Zhao et al. 2011 ). 
4. C02 inhalation treatment in some studies has shown to be as effective in 
treating AOP as theophylline. C02 is the physiological stimulus for breathing in 
mammals. As a result, when the C02 baseline decreases below the apnea threshold 
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apneic episodes are likely to occur. In fact, a C02 rise of 1-2 mm Hg above this apnea 
threshold will reduce or abolish apnea (Zhao et al. 2011 ). 
5. Orogastric feeding tube placement is often beneficial to infants suffering from 
AOP because nasogastric tubes have the tendency to increase nasal airway resistance by 
as much as 50%. Nonetheless, studies are conflicting suggesting that while orogastric 
feeding tubes can drastically decrease the unnecessary nasal airway resistance caused by 
nasogastric tubes, other studies have shown that the placement of a feeding tube had no 
significant effect on reducing bradycardia and desaturation (Zhao et al. 2011). 
6. Thermoneutral range may be a key factor in preventing and regulating AOP. In 
fact, incubated babies in which the incubator temperature was at 30.4 °C had less apneic 
episodes than babies incubated at temperatures at 32.5 °C. While overheating may be a 
factor in AOP, there is little evidence of this and research is still ongoing (Zhao et al. 
2011). 
7. Red blood cell transfusions for the treatment of AOP are one of the most 
controversial methods of treatments. While it is known that anemia can lead to AOP, red 
blood cell transfusions to increase oxygen-carrying capacities may not necessarily 
improve or prevent AOP. In fact, in some studies it was entirely unclear whether red 
blood transfusions had a direct correlation with apnea (Zhao et al. 2011 ). 
D. Pharmacological Treatment for Neonatal Apnea & Apnea of Prematurity 
The first pharmacological treatment for apnea mostly involved the administration 
of supplemental oxygen. However, after decades of research it was believed that oxygen 
supplementation may do more harm than good (Bhatt-Mehta and Schumacher 2003). 
Since then most pharmacological treatments have involved the use of xanthine 
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derivatives, specifically, methylxanthines. 
The use of methylxanthines to treat apnea dates back to the early 1970s. The two 
most commonly used methylxanthines for treatment of apnea are caffeine ( 1, 3, 7-
trimethylxanthine) and theophylline (1, 3-dimethylxanthine) (Brouillette et al. 1990, 
Bhatt-Mehta and Schumacher 2003). Aminophylline, theophylline, and caffeine, have 
been shown to reduce the frequency of apnea and the need for mechanical ventilation 
during the first seven days of therapy (Schmidt et al. 2006). Methylxanthines are 
typically prescribed in very preterm infants until the gestational age of 34 to 35 weeks 
(Schmidt et al. 2006). Theophylline treatment is effective in some infants with idiopathic 
apnea (Brouillette et al. 1990). 
Although theophylline and caffeine have a variety of similar pharmacological 
effects (e.g. excitation of the CNS) and only differ in structure by one methyl group 
(Persson 1982), their specific effects on respiration and ventilatory C02 responses are 
remarkably different. Moreover, methylxanthine structure-activity studies have shown 
that methylxanthines differ in potency as antagonists of A1 and A2 adenosine receptors, as 
a consequence of their chemical structures (Rall 1990). 
While, the methylxanthines occurring naturally only consist of caffeine (fig. 6) 
theophylline (fig. 10), and theobromine (fig. 8); xanthine derivatives are constantly being 
synthesized in order to produce xanthine with more potent and flexible properties. It has 
been demonstrated that substituents of alkyl groups at positions 1, 3, and 7 as well as the 
addition of aromatic, cyclohexyl and cyclopentyl groups at positions 8 can dramatically 
influence the potency of methylxanthine's ability to inhibit cyclic nucleotide 
phosphodiesterase and antagonize receptor-mediated actions of adenosine (Rall 1990). 
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Methylxanthine's effect as an antagonist of adenosine subtype receptors not only 
competitively inhibits the actions of these adenosine receptors to such vital processes as 
cardiovascular and respiration stimulation but is believed to do so in accordance with its 
general chemical structure and its affinity for either At or A1 receptors .. 
V. Xanthines 
Xanthine or xanthic acid (3, 7-dihydro-purine-2, 6-dione) (fig. 4) is a purine base 
found in tissue and fluids of humans and other organisms. Xanthine is a water insoluble 
toxic yellowish white powder (Voet et al. 2008). Xanthine is a product of the purine 
degradation pathway and can be created from 1) guanine by guanine deaminase 2) 
hypoxanthine by xanthine oxidoreductase, and 3) xanthosine by purine nucleoside 
phosphorylase (PNP). Xanthine is converted to uric acid by xanthine oxidase (fig. 5) 
(Voet et al. 2008). 
Initially, xanthines were prematurely given a low priority in drug research. Beta 
adrenergic (B2; receptor that reacts to adrenaline) receptor stimulants and cromoglycate 
use, as well as prostaglandin studies, superseded the use of xanthines. Moreover, 
xanthine use was most likely delayed by the prevalence of the "phosphodiesterase 
hypothesis". It was assumed that the bronchodilator effects of xanthines, specifically, that 
of theophylline, reflected the inhibition of phosphodiesterase enzymes; when in fact 
theophylline is a poor phosphodiesterase inhibitor at therapeutic concentrations. It is at 
these therapeutic dosages that theophylline acts as a potent adenosine receptor antagonist 
(Persson 1982). 
Xanthines have been extensively researched in both basic and clinical settings. 
One of the most researched areas involving xanthines is that relating its structure-activity 
relationships. It has long been known that variations of the chemical substituents can 
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bring about significant alterations in the biological actions of xanthine derivatives 
(Persson 1982). 
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Figure 4: Xanthine. 2, 6-Dihydroxypurine, 
CsH4N402, MW 152.11 (Sigma-Aldrich 2012). 
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Figure 5: Xanthine Biosynthesis (Voet et al. 2008). 
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As a result, it is possible to create antiasthmatic xanthines (e.g. Enoprofylline, 3-
propylxanthine) which lack a number oftheophylline-like extrapulmonary effects. These 
xanthine derivatives also seem to lack the ability to antagonize adenosine receptors in 
smooth muscle, cardiac muscle and nervous tissue where theophylline behaves as a 
potent competitive antagonist (Persson 1982). 
It is now known that 1) substitution in the 3-position is sufficient for potent 
bronchodilator activity, 2) substitution in the 1-position is essential for adenosine 
receptor antagonism, 3) substitution in the 9-position leads a general loss of potency, and 
4) substitution in the 7-position leads to decreased bronchodilation (Persson 1982). 
VI. Methylxanthines 
Methylxanthines are derivatives of xanthines. The addition or substitution of a 
methyl group to xanthine produces different methylxanthines. The most common types 
of methylxanthines are caffeine (1, 3, 7-trimethylxanthine), theophylline (1, 3-
dimethylxanthine, paraxanthine (1, 7-dimethylxanthine), theobromine (3, 7-
dimethylxanthine ), and aminophylline (theophylline or ethylenediamine ), which are 
shown in figs. 6-10. These methylxanthines are important as 1) competitive nonselective 
phosphodiesterase inhibitors which reduce inflammation and innate immunity, and 2) 
nonselective adenosine receptor antagonists, which inhibit adenosine and thus inhibit 
sleepiness. Nonetheless, it has been proven that different xanthine analogues show 
varying degrees of potency either as a phosphodiesterase inhibitor or as adenosine 
receptor antagonists. This synthesis of various xanthine derivatives based on varying 
degrees of methyl, alkyl, aromatic, cyclohexyl, and cyclopentyl substitution have allowed 
researchers and scientists to manipulate and control the physiological effects of 
methylxanthines. 
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Figure 6: Caffeine.1,3,7-Trimethylxanthine, 
2, CsH10N402, MW 194.19 
180.16 (Sigma-Aldrich 2012). 
Figure 8: Theobromine. 3,7-
Dimethylxanthine C1HsN402 MW 180.16 
(Sigma-Aldrich 2012). 
2 
Figure 7: Aminophylline. 
Theophylline, Ethylenediamine. 
C1HsN402*0.5C2HsN2, MW 210.21 
(Sigma-Aldrich 2012). 
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Figure 9:Paraxanthine. 1,7-
Dimethylxanthine C1HsN402 , MW 
180.16 (Sigma-Aldrich 2012). 
Figure 10: Theophylline. 
1,3- Dimethylxanthine, C1HsN402, MW 180.16 
(Sigma-Aldrich 2012). 
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A. Types of Xanthine/Methylxanthine Substituents 
Methylxanthines (e.g. caffeine, theophylline) exhibit a variety of pharmacological 
effects, many of which are due to the antagonism of A1 and/or Az adenosine receptors. 
Some actions (e.g. bronchodilation, antiasthmatic effects) are due to the inhibition of 
phosphodiesterases. 8-phenyl-, and 8-cycloalkyl-1, 3-dialkylxanthines have low activity 
as phosphodiesterases inhibitors and are largely classified as selective At receptor 
antagonists (Shamim et al. 1989). 
"Propyl moieties at 1-and 3-positions confer higher potency than ethyl or methyl 
moieties, particularly at the At receptors; thus 1, 3-dipropylxanthine is significantly more 
potent than theophylline" (Shamim et al. 1989). Larger alkyl groups at the 1-, and 3-
positions are for the most part not tolerated and are no more potent than theophylline as 
adenosine receptor antagonists (Shamim et al. 1989).0ne of the most selective xanthine 
derivatives at adenosine receptors is 1, 3-dipropyl-8-phenylxanthine and its selectivity is 
attributed mainly to the presence of a phenyl group at the 8-position (Shamim et al. 
1989). 8-Cycloalkyl moieties ( cyclopentyl, cyclohexyl) in theophylline and 1,3-
dipropylxanthine markedly increase activity at At receptors compared to Az receptors 
making them highly potent selective A1 receptor antagonists and thus valuable research 
tools. They are also only moderately soluble in water (Shamim et al. 1989). The polar 
substituents such as p-carboxy and p-sulfo on the 8-phenyl ring result in the loss of 
selectivity at At receptors but are still powerful research tools because the sulfo 
analogues, for instance, do not penetrate into cells, thus eliminating any side effects on 
intracellular enzymes (Shamim et al. 1989). 
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In the initial attempt to develop selective Ai and/or Az adenosine receptor 
antagonists, 8-phenylcaffeine was synthesized. The 8-phenyl substituent did not 
significantly enhance antagonist activity at Ai or Az adenosine receptors. The effects of 
8-phenyl moieties alone or with p-carboxy and p-sulfo substituents and 8-cycloalkyl 
moieties such as cyclopentyl and cyclohexyl were also compared to the activity of 
caffeine, 1,3-dipropyl-7-methylxanthine, 1-isoamyl-3-isobutylxanthine, 1-
methylxanthine, 1-propylxanthine, and 3-propylxanthine (Shamim et al. 1989). 
Attaching an 8-phenyl group to caffeine only slightly increases potency, 8-(p-
carboxyphenyl) caffeine is less active then caffeine, and 8-(p-sulfophenyl) caffeine has 
virtually no activity at Ai and only modest activity at Az. Both 8-cyclopentylcaffeine and 
8-cyclohexylcaffeine are potent and selective for the Az receptor. This was unexpected 
since 8-cyclohexyltheophylline ( CPT) (fig. 11) and 8-cyclopentyltheophylline are both 
potent and selective for the Ai receptor. It appears that the 7-methyl group of the 8-
cycloalkylcaffeines selectively reduces affinity for rat brain Ai receptors (Shamim et al. 
1989). 
8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) (fig. 12) and 8-cyclohexyl-1, 3-
dipropylxanthine are two of the most potent and selective antagonists for Ai receptors 
(Shamim et al. 1989). 
1. Cyclopentyltheophylline (CPT) 
Another potent selective Ai receptor antagonist is 8-cyclopentyl-1, 3-
dimethylxanthine (CPT). This is due primarily to the 1, 3-methyl and 8-cycloalkyl 
(cyclopentyl) moiety substitutions (Shamim et al. 1989), 
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Figure 11: Cyclopentyltheophylline (CPT). 8-cyclopentyltheophylline also known as 
8-cyclopentyl-1,3-dimethylxanthine, or 8-cyclopentyl-1,3-dimethyl-7 H-purine-2,6-dione, 
C12H16N402 MW 248.28 (Sigma-Aldrich 2012). 
2. Dipropylcyclopentylxanthine (DPCPX) 
To date dipropylcyclopentylxanthine or 8-clopentyl-l, 3-dipropylxanthine 
(DPCPX) is one of the most potent and selective antagonists for A1 receptors. This is due 
primarily to the 1, 3-propyl moiety and the 8-cycloalkyl (cyclopentyl) moiety 
substitutions (Shamim et al. 1989). 
Figure 12: Dipropylcyclopentylxanthine (DPCPX). 8-cyclopentyl-1, 3-
dipropylxanthine or 8-cyclopentyl-1, 3-dipropyl-7H-purine-2, 6-dione. C16H24N402 MW 
304.39 (Sigma-Aldrich 2012). 
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VII. Adenosine 
A. What is Adenosine? 
Adenosine is a purine nucleoside consisting of a molecule of adenine connected 
to a ribose sugar molecule via a glycosidic bond (fig. 13) (Klaasse et al. 2008). Adenine 
is a purine-based nucleobase (similar to guanine) involved in many biological functions, 
including cellular respiration, and protein biosynthesis (as a component of DNA and 
RNA) (fig. 14) (Eltzschig 2009). 
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Figure 13: Adenosine (Sigma-Aldrich 2012). Figure 14: Adenine (Sigma-Aldrich 2012). 
B. Adenosine Generation and Structure 
Adenosine, like adenine, plays a crucial role in a variety of basic biological 
functions (e.g. nucleotide biosynthesis, cellular energy metabolism). Extracellularly 
adenosine serves as a signaling molecule and its biological functions are in response to 
the activation of adenosine receptors (ARs) localized on the extracellular surface of the 
cell membranes. Particularly during times of cell distress (e.g. inflammation, hypoxia, 
and acute injury), adenosine levels increase due to the phospho-ester hydrolysis of its 
precursor molecules: ATP ( 5' -adenosine triphosphate ), ADP ( 5'-adenosine disphosphate) 
and AMP ( 5'-adenosine monophosphate ). These precursor molecules each contain the 
nucleoside adenosine, bound to a varying number of phospho-esters attached to the 5'-
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designated atom of its ribose sugar ring. First, cells release intracellular stored 
nucleotides, typically in the form of ATP or ADP. These extracellular ATP and ADP 
nucleotides are then converted to AMP by the ecto-apyrase (CD39). CD39 is a widely 
expressed surface-bound enzyme that not only is responsible for extracellular adenosine 
production by generation of AMP but also catalyzes the key step in the extracellular 
breakdown of ATP and ADP. Finally, adenosine is formed by the 5'-ecto-nucleotidase 
(CD73), a membrane bound glycoprotein that converts extracellular AMP to adenosine 
(fig. 15; Eltzschig 2009). 
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Figure 15: Adenosine Biosynthesis (Eltzschig 2009). 
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Extracellular adenosine plays a critical role in tissue adaptation to limited oxygen 
availability. Several studies have found that extracellular adenosine levels are elevated 
during conditions of hypoxia. In one study, volunteers exposed to normoxia or moderate 
hypoxia (oxygen saturation of 80% over 20 min) had adenosine levels increase from 
approximately 20 nM to over 50 nM concentrations. Adenosine tissue concentrations 
increased 5-fold in hearts and kidneys exposed to ischemia (Eltzschig 2009). 
Adenosine is the endogenous ligand for the adenosine receptors. Adenosine, as 
mentioned before, is continuously formed extracellularly by dephosphorylation of ATP, 
ADP and/or AMP to adenosine by NTPDases (ectonucleoside triphosphate 
diphosphohydrolases). Most adenosine receptor agonists are analogues of adenosine, 
modified by N6, C2 and C8 substitutions at the adenine base, and CS' modifications of 
the ribose moiety. Antagonists lack the ribose group and usually possess a mono-, bi-, or 
tricyclic core structure (e.g. caffeine which contains a xanthine as basic structure) 
(Klaasse et al. 2008). 
VIII. Adenosine Receptors 
There are two main families of purine receptors, adenosine or P 1 receptors, and 
P2 receptors, which recognize and respond mainly to ADP, ATP, uridine diphosphate 
(UDP), and uridine triphosphate (UTP) (Ralevic and Bumstock 1998). There are four 
distinct subtypes of Adenosine/Pl receptors: Ai, A1A, A1B, and AJ. Ai and Az receptors 
were described by Van Calker et al. ( 1979). They suggested that adenosine could be 
antagonized by methylxanthines and the order of potency of these adenosine analogs was 
different between Ai and Az receptors. Van Calker et al. (1979) presented findings that 
activation of Ai and Az receptors by adenosine and its derivatives inhibited, via Ai, or 
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stimulated, viaA2, adenylate cyclase. A2 receptors are divided into two subtypes: A2A 
and A2B. This subdivision is based upon evidence that suggests adenosine-mediated 
stimulation of adenylate cyclase in the rat brain is effected via distinct high affinity 
binding sites and low affinity binding sites; the two sites are called AiA and A2B, 
respectively (Ralevic and Bumstock 1998). 
Since, individual ARs result in different biologic functions, it is important to point 
out that extracellular adenosine signaling effects are strongly influenced by the relative 
expression pattern of ARs on the extracellular surface of an individual cell type. ARs 
contain seven transmembrane spanning domains and are coupled to intracellular GTP 
(guanosine triphosphate )-binding proteins, utilizing intracellular cyclic AMP ( cAMP) as 
a second messenger. Adenosine activates A 1, A2A or A3 ARs with EC50 (effective 
concentration that gives half-maximum response) values between 10 nM to 1 µM. In 
contrast, activation of the A2B AR generally requires adenosine levels that exceed 10 
µM. Under physiological conditions, normal adenosine concentrations remain lower 
than 1 µM. Several other factors, including receptor density and the functionality of the 
intracellular signaling pathways coupled to adenosine receptors, are important 
determinants of signaling effects (Eltzschig 2009). 
There is only low homology between cloned A1, A2A, A2B, and A3 receptors. For 
example, the homology between rat A 1 and A2 receptors is only 45%. The homology 
between AiA and A2B receptors is also minimal: 46% in rats, and 61 % in humans 
(Ralevic and Bumstock 1998). 
Adenosine receptors occur throughout the body and exert many different 
functions, both in the CNS and in the periphery. However, adenosine function is almost 
entirely dependent on the type of adenosine receptor (Klaasse et al. 2008). 
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The A1R is highly prevalent within the CNS, with high levels in the cerebral 
cortex, cerebellum, hippocampus, thalamus, brain stem and spinal cord. Nonetheless, 
peripheral tissues also express the A1R including: adrenal gland, aorta, bladder, eye, 
heart, liver, pituitary, spleen and stomach. Low levels of A1R are also found in the lung, 
kidney and small intestine. A1R has been associated with cardiovascular effects (e.g. 
reducing heart rate), inhibition of pyrolysis and stimulation of glucose uptake in white 
phagocytes, and the modulation of neurotransmitter release in the CNS. A1R is also 
believed to play a crucial role in anxiety, hyperactivity, bronchoconstriction and the 
agglomerate filtration rate and renin release in the kidney (Klaasse et al. 2008). 
AzAR is also found in the CNS, primarily within the striatum and olfactory 
tubercle. In the periphery it is most prevalent within the blood platelets, leukocytes, 
spleen and thymus, while intermediate levels of AzAR are found in the heart, blood 
vessels and lungs. AzAR is involved in the inhibition of platelet aggregation, exploratory 
activity, aggressiveness, hypoalgesia and the onset ofvasodilatation. It also plays an 
important role in Parkinson's disease, Huntington's disease, Alzheimer's disease, 
ischemia and attenuation of inflammation and neuroprotection (Klaasse et al. 2008). 
A2BR, like A1R and AzAR, is also found in the CNS as well but typically at very 
low levels. In the periphery, however, high levels of AzBR are found in the caecum, large 
intestine and urinary bladder. Lower levels were also detected in the adipose tissue, 
adrenal glands, lung, liver, spinal cord, vas deferens, pituitary and ovaries. While there is 
little known about the actual functional significance of AzBR it is believed to play a role 
in mediating vasodilatation in the aorta, the renal artery and coronary artery of different 
species. There is also a link with AzBR with certain allergic and inflammatory disorders 
(Klaasse et al. 2008). 
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IX: Structure and Binding of Adenosine Receptors 
All adenosine receptors couple to G proteins. In common with other GPCR's they 
contain seven transmembrane (TM) domains of hydrophobic amino acids, each believed 
to constitute a a-helix of approximately 21-28 amino acids. The N-terminal of the protein 
lies on the extracellular side of the membrane. The C-terminal lies on the cytoplasmic 
side of the membrane. The three-dimensional arrangement of the a-helical TM domains 
forms the ligand binding site where the agonists are believed to bind within the upper 
half of the pore. The transmembrane domains are connected by three extracellular and 
three cytoplasmic hydrophilic loops of unequal size (fig. 16) (Ralevic and Bumstock 
1998). 
Agonist & antagonist 
recognition site 
/ 
Extracellular 
Intracellular 
COOH-----~ 
Figure 16: A1 Adenosine Receptor. Similar to other Adenosine receptors the AiR has 
seven putative transmembrane domains (Ralevic & Bumstock 1998). 
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It is believed that it is the amino acid (e.g. Histidine between TM6 and TM7, threonine 
in TM7, Glu 16 in TMl and Asp 55 in TM) residues within the transmembrane regions 
that are crucial for ligand binding and specificity. With the exception of the distal 
( carboxyl) region of the second extracellular loop, the extracellular loops, the C-terminal 
and the N-terminal do not seem to be involved in ligand binding (Ralevic and Bumstock 
1998). 
Agonists with greater stability than adenosine are typically produced by 
modifying the N6 and C2 positions of the adenine ring and the 5'-position of the ribose 
moiety of adenosine (Ralevic and Bumstock 1998). Xanthines and xanthine derivatives, 
including the natural derivatives theophylline and caffeine, are non-selective 
adenosine/Pl receptor antagonists (Ralevic and Bumstock 1998). 
X. The Relationship between Methylxanthines & Adenosine 
When the intended use of these receptors is a potential drug target it is important 
to understand the level of activation that is achieved by endogenous adenosine acting at 
the receptors in different locations. Two factors are of importance: 1) the potency of 
adenosine as an agonist at the different adenosine receptors, and 2) the levels of 
adenosine that are found under physiological and pathophysiological conditions. 
Moreover, the potency of endogenous adenosine (the affinity of adenosine to its 
receptors) is dependent both on receptor number, and on the type of response measured 
(Fredholm 2010). 
There is always a finite intracellular concentration of adenosine. In addition, 
because most (if not all) cells possess equalibrative adenosine transporters, there is also a 
finite level of adenosine in the extracellular space, even under basal conditions. 
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Typically, this is in the range of 30-200 nM. Adenosine levels increase substantially via 
several different mechanisms. First is the formation of intracellular adenosine and its 
export via transport proteins. Second is of adenosine formation in the extracellular space 
from adenine nucleotides released from cells. Moreover, adenosine is formed 
intracellularly when there is a conflict between the rates of ATP synthesis and ATP 
utilization (e.g. work load enhanced, supply of oxygen and glucose is limiting, as in 
ischemia) (Fredholm 2010). 
It has been demonstrated that theophylline and other methylxanthines are very 
effective antagonists of adenosine receptors, and thus the actions of adenosine (e.g. 
regulates sleepiness). This antagonism was the basis for the first theorized notion that 
there are specific adenosine receptors at which methylxanthines act as antagonists. It is 
believed that many of the effects of xanthines are in fact due their inhibition of the 
actions of endogenous adenosine. Xanthines have shown to act as antagonists on AiR, 
Ai.AR, and AzBR however AJR is not affected by reasonable concentrations of most 
xanthines. Moreover, it was discovered that xanthine structure plays a critical role in 
determining the antagonistic potency of xanthines at adenosine receptors. Since then 
several more potent xanthines (as compared to caffeine and theophylline), and xanthines 
that are receptor subtype selective have been synthesized. Many non-xanthine 
antagonists as well as several receptor-selective agonists have also been synthesized. The 
selectivity of these agonists/antagonists has led to some very effective pharmacological 
tools (Fredholm 2010). 
Many of the most potent and selective antagonists have demonstrated 
physiochemical properties that have both strained and delayed their use in vivo in 
animals and man. To bypass this dilemma researchers have created mice with targeted 
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deletions of one or more adenosine receptors. These genetically modified mice have been 
very useful in determining the roles of adenosine receptors. Moreover, there is little 
proven consequence of these knockout mice and very few if any adaptive changes. An 
even more powerful technique is to combine the use of drugs with these knock-out mice. 
In fact, it was this technique that elucidated the fact that caffeine works by blocking 
adenosine receptors. It has also allowed researchers to determine the specific 
physiological and pathophysiological role of adenosine receptors. A 1 receptors are 
involved with: decreased renal blood flow, conglomeration feedback, inhibition of 
pyrolysis, inhibition of neurotransmitter release, inhibition of insulin/glucose release, 
reduced heart rate, sleep, analgesia, and preconditioning. AzA receptors are involved 
with: wakefulness, locomotion, degeneration, impressionability, vasodilatation, inhibition 
of platelet aggregation, and angiogenesis. AzB receptors are involved with: vascular 
integrity, preconditioning, and pain. A3 receptors are involved with: increased mast cell 
activation, airway contraction, inflammatory pain, and white cell chemotaxis (Fredholm 
2010). 
XI. Related Studies 
To date there have not been many experiments concerning the efficacy ofDPCPX 
and CPT on respiration stimulation, specifically on that of neonatal rats. Most of the 
previous studies concerning the treatment of sleep apnea involves caffeine and 
theophylline. It has been shown that methylxanthines, specifically caffeine and 
theophylline, stimulate respiration and help treat apnea. In addition some of related 
studies concerning methylxanthine treatment have a very similar methodology, as seen in 
this study. This is exemplified in the following three related studies. 
53 
In the article, Caffeine Therapy for Apnea of Prematurity, and the follow-up 
article Long-Term Effects of Caffeine Therapy for Apnea of Prematurity, Schmidt et al. 
2006, discuss their findings concerning the short-and long-term efficacy and safety of 
methylxanthine therapy for apnea of prematurity in infants with very low birth weight. 
Although, methylxanthines have shown promise in treating apnea, the fact that 
methylxanthines and xanthine analogs inhibit adenosine receptors calls into question 
their potential for harm. Adenosine is not only important in such vital processes as 
cardiovascular and respiratory function but preserving brain ATP levels and cells during 
experimental hypoxia an ischemia conditions as well. Moreover, aside from inhibiting 
these vital receptors methylxanthines also increase oxygen consumption in preterm 
infants and diminish growth. 
To study these potential effects of methylxanthines, 2006 infants (with birth 
weights between 500 to 1250 grams during the first 10 days of their life) were randomly 
assigned to receive either caffeine or placebo, until drug therapy of apnea was no longer 
needed. The short-term effects were examined first. Their findings suggested the 
following: 1) caffeine substantially reduced the frequency ofbronchopulmonary 
dysplasia; 2) caffeine diminished weight gain in comparison to placebo groups; 3) infants 
in the placebo group required respiratory support for one more week longer than caffeine 
groups; and 4) caffeine reduced the frequency of patent ductus arteriosus (Schmidt et al. 
2007). 
Although, the findings of this experiment produced little data suggesting any 
significant potential short-term harm for neonatal apnea infants treated with caffeine, it 
was determined that the short-term outcomes are insufficient to assess the overall 
efficacy and risk of neonatal interventions. The long term effects were studied from the 
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same group at a corrected age of 18-21 months. The findings suggested the following 
about caffeine: 1) improved the rate of survival without neurodevelopment disability; 2) 
reduced the incidence of cerebral palsy and cognitive delay; 3) had no effects on death 
rates, blindness, or hearing loss; and 4) reduced the incidence of severe retinopathy of 
prematurity. Ultimately, they were able to conclude that the overall benefits of 
methylxanthine therapy as used in their trial outweigh any potential risks up to 2 years 
after very preterm birth; but more long terms studies are needed to accurately determine 
the validity of this (Schmidt et al. 2007). 
Besides treating disorders relating to hypoxia and ischemia, methylxanthines can 
also be used to treat conditions related to C02, specifically, a decreased ventilatory 
response to C02. In the article, Effect of Caffeine on the Ventilatory Response to C02 in 
Newborn rats, McGilliard and Saeki (2002) from Eastern Illinois University examined 
the effect of various doses of caffeine on the ventilatory response to C02. Due to 
premature neonates not having a mature respiratory system, specifically the immaturity 
of the medulla, not only does the infant cease in breathing but the chemoreception 
between carbon dioxide (a respiratory stimulant) levels and ventilatory responses of 
infants is also at risk of malfunctioning. This decreased ventilatory response has been 
implicated in a variety of breathing disorders, especially sudden infant death syndrome. 
Although both theophylline and caffeine have been known to treat neonatal apnea, 
evidence that theophylline increases the ventilatory response to C02 is much more 
conclusive. Based on evidence that caffeine might function to increase the ventilatory 
response to C02 as well as the similarities of immature respiratory systems in infants and 
newborn rats, McGilliard and Saeki (2002) devised a study in order to investigate the 
effect of three different doses of caffeine on the respiratory pattern and ventilatory 
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response to C02 of newborn rats (McGilliard 2002). They were able to conclude that 
although there was no significant effect of caffeine on the minute ventilation and 
inspiratory flow response to C02, there was a trend toward increasing slopes of the C02-
response curves with the 80 mg/kg dose of caffeine. Ultimately, although there were 
interactions among variables, there were no trends. A possible suggestion is that caffeine 
only stimulates the ventilatory responses to C02 at higher doses than those tested. This 
study compares to the study conducted by Rigatto et al. (1975) in which C02 increased 
minute ventilation in newborn premature infants. 
One of the most specific studies concerning the use of methylxanthines in 
newborn rats for treatment of neonatal apnea, is the study conducted by McGilliard et al. 
(1990), in which they examined the effects of xanthine analogs on the respiratory control 
in newborn rats. This study was based on evidence that substitution of an alkyl group on 
the 3-position of the xanthine nucleus resulted in increased bronchodilator potency, 
substitution on the 7-position decreased bronchodilator potency, and substitution at the 1-
position is important in adenosine antagonism and central nervous system stimulation. 
They examined the dependence and structural requirements for respiratory stimulation of 
( 4-to-7-day old rats) using five different alkylxanthines. They were able to determine the 
following: 1) Theophylline (THEO, 1, 3-diMX, 10-40 mg/kg) increased minute 
ventilation (VE) in a dose related manner by as much as 45 % over baseline. Increases 
were observed in both tidal volume (VT) and respiratory rate (f); 2) Caffeine (CAF, 160 
mg/kg) produced significant increases in VE (62 % baseline) primarily due to VT, with 
. ' 
no significant change in f; 3) 1-MX (40 mg/kg) increased VE by almost 20%, primarily 
by increasing f; and 4) Neither 3-MX (10-80 mg/kg) nor enprofylline (3-propylxanthine, 
10-40 mg/kg) produced significant changes in VE. They concluded that substitution at 
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the 1-position of the xanthine nucleus is essential for respiratory stimulation and that the 
stimulant effect is enhanced by substitution at the 3-position and reduced by substitution 
at the 7-position. VT potency rank was THEO>CAF>l-MX and the potency rank for 
stimulation off was THEO=l-MX>> CAF. Ultimately, they were able to provide 
evidence that the differences in potency rank demonstrated that the rate and volume 
components of the respiratory control of newborn rats were pharmacologically 
influenced. Furthermore, antagonism of adenosine receptors is necessary for 
alkylxanthine-induced respiratory stimulation. 
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CHAPTER 3: METHODS 
All experimentation was conducted on the campus of Eastern Illinois University, 
Charleston, Illinois, in the Life Science Building. Research was conducted under the su-
pervision of Dr. Kip L. McGilliard in the Department of Biological Sciences. Animal 
procedures were approved by the Institutional Animal Care and Use Committee at East-
ern Illinois University (protocol #04-012). 
The respiratory apparatus consisted of a body plethysmograph attached to a pneu-
motachograph. The body plethysmograph was a hollow tube approximately 8 cm in 
length and 2.6 cm in diameter. One end of the tube was covered with a square oflatex 
rubber sheet with a hole cut in the center by a cork borer (sizes 5 to 8, depending on the 
size of the rat). The other end of the plethysmograph was plugged with a #5.5 one-hole 
rubber stopper (fig. 17). The plethysmograph was connected to a #0000 Fleisch pneumo-
tachograph (Phipps & Bird, Richmond, VA) by a 12 cm length of flexible tubing. The 
pneumotachograph was connected by two flexible tubes to a DP 103-10 differential pres-
sure transducer (Validyne Engineering, Northridge, CA), which fed into a CD19A carrier 
demodulator (Validyne Engineering). The signal from the carrier demodulator was deliv-
ered via an 8-pin connector to an ETH-255 Bridge/Bio Amplifier (CB Sciences, Dover, 
NH). The amplified signal was carried via a BNC-BNC connector to a PowerLab 200 
(ADinstruments, Colorado Springs, CO) for recording, storage, and analysis by a Dell 
computer (fig. 18). The plethysmograph was placed inside a 6.5 cm ID water-jacketed 
cylinder set at 35 °C (fig. 17) to maintain rat body temperature during the experi-
ment. Water was heated and pumped through the water jacket by a Haake L series water 
bath (Haake Instruments, Rochelle Park, NJ). 
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Flow data from the plethysmograph were recorded and integrated by the Chart 
software (ADinstruments), yielding four channels ofrecorded data. To eliminate any 
drift in the volume recording (Channel 2), Channel 3 computed input was turned on and 
the raw data recording was adjusted to zero using the amplifier Channel 1 offset knob. 
Channel 2 was then periodically monitored for drift, indicated by a positive or negative 
sloping volume signal when no breathing was being recorded. If drift occurred, adjust-
ments were made accordingly. Volume calibration involved forcing exactly 20 ml of air 
from a syringe through the pneumotachograph in about 5 seconds. 
Newborn Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN) be-
tween 4 and 7 days old were used in all experiments. The rats were reared in the Biologi-
cal Department of Biological Sciences rat breeding facility. Each litter size consisted of 
8 rats. Each rat was only used once. Rats were randomly chosen from each litter. Each 
rat's weight (ranging from 10-19 grams) and sex were recorded. A suitable-sized rubber 
diaphragm was then selected depending on the size of the rat. A thin coat of lubricant (K-
y jelly) was placed around the rim of the plethysmograph and the diaphragm was posi-
tioned on the end of the plethysmograph by a rubber band. The rat was then placed in the 
plethysmograph and its head was forced through the hole in the diaphragm. Plastic cross-
pieces (different sizes depending on the length of each rat) were placed behind the rat to 
prevent it from backing out of the diaphragm. The end of the plethysmograph was then 
plugged with a rubber stopper. The neck was sealed with lubricant to prevent air from es-
caping and to eliminate any irritation caused by the rubbing of the diaphragm against the 
rat's neck. A small plastic cylinder (approximately 2 cm in length and 2 cm in diameter) 
was placed around the rat's head, and held in place with Scotch tape (fig. 17). 
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Figure 17: Body Plethysmograph (McGilliard 2002). 
Excursions of the chest wall produced flow of air into and out of the cylinder 
which were measured by the pneumotachograph and recorded as flow, volume, and 
breath count (fig. 18). 
Figure 18: PowerLab Setup (McGilliard 2002). 
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In an attempt to acclimate the rat to the conditions (e.g. temperature, space) of the 
plethysmograph, two c01;itrol measurements (e.g. non-treated standard recordings of res-
piratory variables) were conducted for a total time of approximately 10 minutes. After 
the initial control period, and without removing the animal from the apparatus, each rat 
was injected subcutaneously by a 26 gauge x 0.5 in needle with either cyclopentyltheo-
phylline (CPT) or 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), or saline. Initial experi-
mentation began with lower doses that is 10, 20 and 40 µg/kg of either CPT or 
DPCPX. Injection volumes were 5 µl/g body weight. To achieve the doses of 10, 20 and 
40 µg/kg, drugs were prepared in concentrations of2, 4, and 8 µg/ml, respectively. Dos-
ages of CPT and DPCPX were then increased to either 80, 160, 320, or 640 µg/kg. Six 
groups of eight rats each were administered 5 µl/g of 16, 32, or 64 µg/ml of either CPT 
or DPCPX. For the 2 groups of eight rats each receiving treatments of 640 µg/kg, they 
were administered 64 µg/ml at twice the standard injection volume (i.e. 10 µl/g) of either 
CPT or DPCPX. The remaining group of eight rats was used as a saline control, receiv-
ing s.c. injections of 0.9% sodium chloride only. Each of these rats was administered 5 
µl/g body weight of saline. 
Respiration was recorded continuously and measurements were taken at ~5 mi-
nute intervals over a period of 60 minutes. Respiratory air flow was recorded by the Pow-
erLab unit at a rate of 100 samples/s. Flow rate was then converted by the Chart software 
(fig. 19) to volume. Minute ventilation (volume of gas exhaled from a person's lung in 
one minute; VE), respiratory rate (the number of breaths taken per minute; f), and tidal 
volume (the amount of air moved into and out of the lungs during normal breathing; VT) 
were determined. The data were further analyzed for time of inspiration (the duration of 
each inspiration; T 1), time of expiration (the duration of each expiration; TE), total time of 
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each breath (T TOT), and mean inspiratory flow (average rate of air flow during inspira-
tion; MIF = VTIT1) (see Appendix for complete definitions of the respiratory varia-
bles). Channel 1 measures the flow of air through h the transducer in Iiters/s; Channel 2 
shows cumulative volume in ml (total expired volume over time); and Channel 3 shows 
the count of breaths. 
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Figure 19: Example of LabChart Data (McGilliard 2002). 
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VE, f, VT, T1, TE, TTOT, and MIF were calculated for each rat at approximately 5 minute in-
tervals for a period of 60 minutes. 
Both 8-cyclopentyl-l , 3-dimethylxanthine (8-cyclopentyltheophylline, CPT) and 
8-cyclopentyl-1 , 3-dipropylxanthine ( dipropylcyclopentylxanthine, DPCPX) were pur-
chased from Sigma Chemical Company (St. Louis, MO). 
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One hundred and twenty rats were randomly administered either CPT, DPCPX, or 
saline treatments. In addition (with the exception of saline treatments), each rat was ran-
domly assigned to 7 different treatment groups based on dosage: 10 µg/kg, 20 µg/kg, 40 
µg/kg, 80 µg/kg, 160 µg/kg, 320 µg/kg, 640 µg/kg of either CPT or DPCPX. All drug 
treatment preparations were made on June 29th, 2010. 
Two different stock solutions were made and then serial diluted with 0.9% NaCl 
to make up 6 different working solutions. Drugs were dissolved in a small amount of 1 M 
NaOH, then 0.9% NaCl was added to bring them almost up to the desired volume. Small 
amounts of IM HCl were then added to bring the pH back to about 8. Concentrations of 
the final solutions in µg /ml and injection volumes were: in concentrations of2, 4, and 8 
µg/ml, respectively for 10, 20 and 40 µg/kg, and 5 µl/g of 16, 32, or 64 µg/ml for 80, 
160, and 320 respectively of either CPT or DPCPX. For the highest dose (640 µg/kg): 
64 µg/ml was administered at twice the standard injection volume (i.e. 10 µl/g) of either 
CPTorDPCPX 
All graphs and calculations, were created using LabChart software, Excel and 
Sigma Plot 11. Results are displayed as mean and mean % changes from pre-drug con-
trols in all respiratory variables over time. These mean % changes were tabulated and 
gathered from the mean raw data values for each respiratory variable. Since each rat 
served as its own control mean % changes were depicted as opposed to the raw data be-
cause it eliminates some of the variation between rats and provides a more accurate illus-
tration of treatment differences. The standard error of mean (SEM) for all respiratory var-
iables was calculated from 96 data points (8 rats x twelve; 5 minute increments over ape-
riod of one hour). 
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Data were analyzed by a two-way analysis of variance (ANOVA) one factor repe-
tition using SigmaPlot 11 software.VE, f, VT, and MIF were analyzed in terms of treat-
ment, time, and treatment x time interaction at all dosages. Tests included equal variance 
tests, multiple comparisons vs. control group (saline), and pairwise multiple comparisons 
(using the Holm-Sidak method; significance level set at a=0.05). 
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CHAPTER4:RESULTS 
I. Minute Ventilation (VE) 
A. VE Percent Change vs. DPCPX Dosage 
In saline-treated newborn rats, VE decreased shortly after saline treatment, 
resulting in ~30% decrease from 5 min to the end of the 60 min recording period (fig. 
20). Effects of drug treatments were evaluated relative to this baseline drop. 
The VE mean percent change was highest and increased (is positive) at dosages 
160 (+21.12 %) followed by 320 (+16.17 %), 640 (+14.95 %), and decreased (is nega-
tive) at dosages 80 (-6.13 %), 20 (-14.15 %), 10 (-15.17 %), and 40 (-21.99 %) µg/kg 
DPCPX respectively. Higher dosages ofDPCPX had higher mean VE (fig. 20). 
Differences in the mean values among the different levels of Treatment were 
greater than would be expected by chance after allowing for effects of differences in time 
(p<Q.001). Differences in the mean values among the different time points is not great 
enough to exclude the possibility that the difference is due to random sampling variabil-
ity after allowing for the effects of differences in treatment (p=.367). The effect of differ-
ent levels of treatment was time dependent (p<0.001). 
Overall, compared to the saline group, DPCPX VE mean was greater than would 
be expected by chance alone for DPCPX 160 (P<0.001), DPCPX 320 (P<0.001), and 
DPCPX 640 (P=0.001) µg/kg (Table 3). In terms of treatment x time, dosages greater 
than 160 µg/kg produced significant results at between ~25-60 minutes. A more detailed 
analysis of the ANOVA results can be seen in Table 1-4 of the appendix. 
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B. VE Percent Change vs. CPT Dosage 
The VE mean percent change is highest and increases (is positive) at dosage 320 
(+ 16.17%) followed by 640(+16.11 %), 20(+13.43 %), and decreases (is negative) at 40 
(-1.35 %), 160 (-5.82 %), 10 (-6.40 %), and 80 (-14.80 %) µg/kg respectively (fig. 21). 
The difference in the mean values among different levels of treatment is greater 
than would be expected by chance after allowing for the effects of differences in time 
(p=0.004).The difference in the mean values among the different levels of time is not 
great enough to exclude the possibility that the difference is just due to random sampling 
variability after allowing for the effects of differences in treatment (p=.941). The effect 
of the different levels of treatment was not dependent on time. There is not a statistically 
significant interaction between treatment and time (p=.344). Overall, compared to saline 
group, CPT mean VE was greater than would be expected by chance compared to saline 
for CPT 20 (P=0.002) and CPT 640 (P=0.001) µg/kg (Table 1). 
C. VE of DPCPX & CPT in Comparison to Saline and Between Equivalent 
Dosages of DPCPX & CPT. 
Compared to the saline treatment group, both DPCPX & CPT had higher mean 
VE at all dosages. DPCPX mean VE was higher at 320, & 640 µg/kg in relation to CPT at 
equivalent dosages. CPT mean VE was higher at 10 µg/kg in relation to DPCPX at 
equivalent dosages. The highest mean VE was at CPT 10 (17.32 ml/min) µg/kg. The 
lowest mean VE was at DPCPX 80 (10.29 ml/min) µg/kg. There is a positive relationship 
between DPCPX dosage & VE. No such correlation can be made for CPT (fig. 22). 
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D. VE Percent Change of DPCPX & CPT in Comparison to Saline Between 
Equivalent Dosages of DPCPX & CPT. 
Compared to the saline treatment group, both DPCPX & CPT had higher VE 
mean percent changes at all dosages. DPCPX VE mean percent change was higher at 80, 
160, & 320 µg/kg compared to CPT at equivalent dosages. CPT VE mean percent change 
was higher at 10, 20, 40 µg/kg compared to DPCPX at equivalent dosages. The highest 
VE mean percent change was at DPCPX 160 ( + 21.18%) µg/kg. The lowest VE mean 
percent change was at DPCPX 40 (-21.99 %) µg/kg. DPCPX VE on average was greater 
at higher dosages. There is no definitive correlation between mean percent change and 
CPT dosage (fig. 23). 
Il. Respiratory Rate (t) 
A. f Percent Change vs. DPCPX Dosage 
In saline treated newborn rats, f decreased shortly after saline treatment, resulting 
in '""40% decrease from 5 min to the end of the 60 min recoding period (fig. 24). The f 
mean percent change is highest and increased (positive) at 160 (+26.81 %) followed by 
320 (+13.81%),640 (+13.32%), 80 (+2.41 %), and decreased (negative) at 20 (-7.67 %), 
10 (-12.84 %), and 40 (-18.61 %) µg/kg. Higher dosages ofDPCPX had higher fmean 
percent changes (fig. 24). 
The difference in the mean values among the different levels of treatment is 
greater than would be expected by chance after allowing for the effects of differences in 
time (p<0.001). The difference in the mean values among the different levels of time is 
not great enough to exclude the possibility that the difference is due to random sampling 
variability after allowing for the effects of differences in treatment (p=0.068). The effect 
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of different levels of treatment does not depend on time (p=.132). Overall, compared to 
saline group, DPCPX mean fwas greater than would be expected by chance compared to 
saline for DPCPX 80 (P=0.024), 160 (P<0.001), 320 (P=0.001) and 640 (P=0.002) 
µg/kg (Table 7). 
B. f Percent Change vs. CPT Dosage 
The fmean percent change is highest and increased (positive) at 640 (+4.8 %) 
and decreased (negative) at 320 (-6.20 %) followed by 40 (-9.45 %), 20 (-10.15 %), 160 
(-10.96 %), 80 (-13.58%), and 10 (-15.34 %) µg/kg respectively. There is no correlation 
between CPT dosage and f mean percent change (fig. 25). 
The difference in the mean values among the different levels of treatment is 
greater than would be expected by chance after allowing for the effects of differences in 
time (p=0.003). The difference in the mean values among the different levels of time is 
greater than would be expected by chance after allowing for effects of differences in 
treatment (p=0.006). The effect of different levels of treatment does depend on time 
(p=0.036). Overall, compared to saline group, CPT mean f was greater than would be ex-
pected by chance compared to saline for CPT 320 (P=0.019) and 640 (P<0.001) µg/kg 
(Table 5). In terms of treatment x time a more detailed analysis of the ANOVA test re-
suits can be seen in Table 6. 
C. f of DPCPX & CPT in Comparison to Saline and Between Equivalent 
Dosages of DPCPX & CPT 
Compared to the saline treatment group, both DPCPX and CPT had higher 
mean fat all dosages. DPCPX mean f was higher at I 0, 320 & 640 µg/kg in relation to 
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CPT at equivalent dosages. CPT had higher mean fat 160 µg/kg in comparison to 
DPCPX at equivalent dosages. The highest mean fwas at CPT 160 (162.3 breaths/min) 
µg/kg. The lowest mean fwas at CPT 80 (110.8 breaths/min) µg/kg. DPCPX f slightly 
higher at higher dosages. No correlation can be made between CPT dosage and f (fig. 
26). 
D. f Percent Change of DPCPX & CPT in Comparison to Saline and 
Between Equivalent Dosages of DPCPX & CPT. 
Compared to the saline treatment group, both DPCPX and CPT had higher f 
mean percent changes at all dosages. DPCPX f mean percent change was higher at 80, 
160, 320, and 640 µg/kg in comparison to CPT. CPT mean percent change was higher 
than DPCPX at 40 µg/kg. The highest f mean percent change was at DPCPX 160 
(+20.95 %) µg/kg. The lowest fmean percent change was at DPCPX 40 (-18. 61 %) 
µg/kg. DPCPX f mean percent change on average was greater at higher dosages. There is 
no definitive correlation between percent change and CPT dosage (fig. 27). 
Ill. Tidal Volume (VT) 
A. VT Percent Change vs. DPCPX Dosage 
In saline treated newborn rats, VT response was quite variable. At 25 min VT 
was increased by 28% and at 30 min it was decreased by 9% (fig. 28). Overall, the VT 
mean percent changes were small. Nonetheless, VTwas highest and increases (positive) 
at DPCPX 160 (+7.43 %) followed by 640 (+3.33 %), and decreases (negative) at 80 (-
0.54 %) followed by 320 (-0.68 %), 10 (-1.43 %), 40 (-2.43%) and 20 (-5.78 %) µg/kg 
(fig. 28). 
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The difference in the mean values among the different levels of treatment is not 
great enough to exclude the possibility that the difference is just due to random sampling 
variability after allowing for the effects of differences in time (p=.902). The differences 
in the mean values among the different levels of time is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for 
the effects of differences in treatment (p=.933). The effect of different levels of treatment 
does not depend on time (p=.172). 
B. VT Percent Change vs. CPT Dosage 
The VT mean percent change was highest and increased (positive) at 20 
(+25.66 %) followed by 640 (+13.36 %), 40 (+10.89 %), 160 (+5.82 %), 10 (+4.65 %), 
320 (+3.28%), and 80 (+0.80 %) µg/kg respectively. There is no correlation between 
CPT dosage and VT mean percent change (fig. 29). 
The difference in the mean values among the different levels of treatment is not 
great enough to exclude the possibility that the difference is just due to random sampling 
variability after allowing for the effects of differences in time (p=.569). The differences 
in the mean values among the different levels of time is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for 
the effects of differences in treatment (p=.159). The effects of the different levels of 
treatment does not depend on time. There is not a statistically significant interaction 
between treatment and time (p=.339). 
C. VT of DPCPX & CPT in Comparison to Saline and Between Equivalent 
Dosages of DPCPX & CPT 
Overall, the differences in VT stimulation ofDPCPX and CPT compared to the 
saline treated newborn rats were negligible (fig. 30). DPCPX mean VT was higher at 40, 
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320, & 640 µg/kg compared to CPT at equivalent dosages. CPT mean VT was higher at 
10 µg/kg compared to DPCPX at equivalent dosages. The highest mean VTwas at CPT 
10 (0.125 ml) µg/kg (fig. 30). The lowest mean VT was at DPCPX 10 (0.85 ml) µg/kg. 
No correlation can be made between CPT dosage and VT (fig. 30). 
D. VT Percent Change of DPCPX & CPT in Comparison to Saline and 
Between Equivalent Dosages of DPCPX & CPT 
Compared to the saline treatment group, DPCPX had lower VT mean percent 
changes at all dosages except 160 µg/kg. CPT had higher VT mean percent changes at 20 
& 640 µg/kg compared to the saline treatment group. CPT VT mean percent change was 
higher at 10, 20, 40, 320, & 640 µg/kg compared to DPCPX at equivalent dosages. The 
highest mean VT was at CPT 20 (+25.66 %) µg/kg. The lowest mean VTwas at DPCPX 
20 (-5.78 %) µg/kg. No correlation exists between DPCPX or CPT VT percent change 
and dosage (fig. 31 ). 
IV. Mean lnspiratory Flow (MIF) (VTIT1) 
In saline-treated newborn rats, MIF decreased shortly after saline treatment, 
saline caused a ~30-40% decrease in MIF (fig. 32). 
A. MIF Mean Percent Change vs. DPCPX Dosage 
The MIF mean percent change was highest and increased (positive) at 160 
(+25.85 %) followed by 320 (+4.38 %), 640 (+l.51 %), and decreased (negative) at 80 (-
1.01) followed by 20 (-8.80 %), 10 (-14.76 %), and 40 (-17.62 %) µg/kg respectively. 
There is an increase in MIF mean percent change with DPCPX dosage (fig. 32). 
The difference in the mean values among the different levels of treatment is 
greater than would be expected by chance after allowing for the effects of differences in 
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time (p=0.004). The differences in the mean values among the different levels of time is 
not great enough to exclude the possibility that the differences is just due to random 
sampling variability after allowing for the effects of differences in treatment (p=.130). 
The effect of the different levels of treatment does depend on time (p=<0.001). 
Overall compared to saline group, DPCPX mean MIF was greater than would 
be expected by chance compared to saline for DPCPX 160 (P<0.001) and 320 (P=0.041) 
µg/kg (Table 11). In terms of treatment x time a more detailed analysis of the ANOVA 
test results can be seen in Table 12. 
B. MIF Percent Change vs. CPT Dosage 
The MIF mean percent change is highest and increased (positive) at CPT 20 
(+22.23 %) followed by 640 (+17.97 %), 320 (+2.64 %), 40 (+0.46 %), and decreased at 
10 (-0.51 %) followed by 160 (-3.20 %), and 80 (-13.15 %) µg/kg. There is no 
correlation between CPT dosage and MIF mean percent change (fig. 33). 
The difference in the mean values among the different levels of treatment is 
greater than would be expected by chance after allowing for the effects of differences in 
time (p=0.001 ). The differences in the mean values among the different levels of time is 
not great enough to exclude the possibility that the differences is just due to random 
sampling variability after allowing for the effects of differences in time (p=.828). The 
effects of the different levels of treatment does not depend on what level of time is 
present. There is not a statistically significant interaction between treatment and time 
(p=.213). 
Overall compared to saline group, CPT mean MIF was greater than would be 
expected by chance compared to saline for CPT 10 (P=0.029), 20 (P<0.001), 40 
(P=0.032), 160 (P=0.034), 320 (P=0.025), and 640 (P<0.001) µg/kg (Table 9). In terms 
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of treatment x time a more detailed analysis of the ANOVA test results can be seen in 
Table 10. 
C. MIF of DPCPX & CPT in Comparison to Saline and Between Equivalent 
Dosages of DPCPX & CPT 
Compared to the saline treatment group, both DPCPX & CPT had higher mean 
MIF at all dosages. DPCPX had higher mean MIF at 20 & 40 µg/kg in comparison to 
CPT at equivalent dosages. CPT MIF was higher at 10 & 160 µg/kg in relation to 
DPCPX at equivalent dosages. The highest mean MIF was at DPCPX 10 (.867 ml/sec) 
µg/kg. The lowest mean MIF was at CPT 80 (.330 ml/sec) (fig. 34). 
D. MIF Percent Change of DPCPX & CPT in Comparison to Saline and 
Between Equivalent Dosages of DPCPX & CPT 
Compared to the saline treatment group, both DPCPX & CPT had higher MIF 
mean percent changes at all dosages. DPCPX had higher MIF mean percent changes at 
80, 160 µg/kg in comparison to CPT at equivalent dosages. CPT MIF mean percent 
change was higher at 10, 20, 40, & 640 µg/kg in relation to DPCPX at equivalent 
dosages. The highest MIF mean percent change was at DPCPX 160 (+25.85 %) µg/kg. 
The lowest MIF mean percent change was at DPCPX 40 (-17.62 %) µg/kg. DPCPX had 
higher MIF mean percent changes at higher dosages (fig. 35). 
73 
50 
40 
30 
~ 20 
·= ~ 10 
ell 
= ~ 0 
u 
~ -10 
= c<: 
~ 
~ -20 
-30 
-40 
-50 
DPCPX VE Mean Percent Change 
0 5 10 15 20 25 30 35 40 45 50 55 60 
Time (min) 
- saline 
- DPCPXlO 
DPCPX 20 
DPCPX 40 
- DPCPX80 
- DPCPX160 
- DPCPX320 
- DPCPX640 
Figure 20: Minute Ventilation (VE) percent change vs. DPCPX dosage. Each curve 
represents the mean values of 8 rats. 
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Figure 21: Minute ventilation (VE) mean percent change vs. CPT dosage. Each 
curve represents the mean values of 8 rats. 
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Figure 25: Respiratory rate (t) mean percent change vs. CPT dosage. Each curve 
represents the mean values of 8 rats. 
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Figure 26: Average respiratory rate (f) of DPCPX & CPT across all dosage ranges. 
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Figure 27: Average respiratory rate (f) mean percent change of saline control, 
DPCPX & CPT across all dosage ranges. Mean percent change is calculated. SEM 
bars are depicted. 
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Figure 28: Tidal Volume (VT) mean percent change vs. DPCPX dosage. Each curve 
represents the mean of 8 rats. 
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Figure 29: Tidal volume (VT) mean percent change vs. CPT dosage. Each curve 
represents the mean values of 8 rats. 
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Figure 30: Average tidal volume (VT) of DPCPX & CPT across all dosage ranges. 
35 
30 
f--o 25 ;;... 20 
~ 
t:fl 
= 15 c: 
-= u 10 
~ .. 5 
0 
-5 
-10 
The saline control group is also depicted. SEM bars are depicted. 
VT Percent Change of DPCPX & CPT in Comparison to 
Saline and Between Equivalent Dosages of DPCPX & 
CPT 
T 
saline 10 20 40 
TI 11 
80 
Dosage (ug/kg) 
160 
T 
I 
320 640 
• Saline 
• DPCPX 
• CPT 
Figure 31: Average tidal volume (VT) mean percent change of saline control, 
DPCPX& CPT across all dosage ranges. Mean percent change is calculated. SEM 
bars are depicted. 
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Figure 32: MIF mean percent change vs. DPCPX dosage. Each curve represents the 
mean values of 8 rats. 
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Figure 33: MIF mean percent change vs. CPT dosage. Each curve represents the 
mean values of 8 rats. 
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Figure 34: Average MIF VTIT1 of DPCPX & CPT across all dosage ranges. The 
saline control group is also depicted. SEM bars are depicted. 
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Figure 35: Average MIF (VTIT1) percent change of saline control, DPCPX & CPT 
across all dosage ranges. Mean percent change is calculated. SEM bars are depicted. 
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CHAPTER 5: DISCUSSION 
This study was based on several key concepts: 1) there is an abundance of 
information concerning neonatal apnea as well as different experimental treatments, 2) 
pharmacological treatments such as methylxanthines have been shown to stimulate 
respiration and provide great potential for treating neonatal apnea, 3) scientific evidence 
supports the efficacy of methylxanthines based on their affinity for and antagonism of 
adenosine A1 receptors, 4) methylxanthine derivatives can be manipulated in terms of 
their potency at A 1 receptors by changing the chemical structure of methylxanthines (i.e. 
substitution of methyl groups at positions 1 and 3, and aromatic cyclohexyl and 
cyclopropyl moieties at the 8 position). The purpose of this experiment was to test the 
following hypotheses: l) both DPCPX and CPT will increase respiration compared to 
saline control treatments, 2) there will be a dose-response relationship between 
DPCPX/CPT treatment and respiratory stimulation, and 3) DPCPX will be a more potent 
respiratory stimulant than CPT based on its higher affinity for A 1 adenosine receptors. 
The purpose of including a saline control is to see what would happen if the 
experiment was performed without injecting the drugs of interest. This is very important 
because past research has shown a decrease in ventilation in the saline-treated newborn 
rats (McGilliard 1984; McGilliard et al. 1990; McGilliard and Saeki 2002). A drug that 
stimulates respiration could actually produce a small decrease in VE and yet that decrease 
would be less than what is produced by saline injection. In relation to the saline treated 
newborn rats, VE decreased shortly after saline treatment, resulting in ~30% decrease 
from 5 min to the end of the 60 min recoding period (fig. 20). This has been commonly 
observed (McGilliard et al. 1984; McGilliard et al. 1990; and McGilliard and Saeki 
2002) and is probably a consequence of the rats adapting to being in the plethysmograph 
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over time. One might think that respiration would be elevated in the first few minutes 
after injection of saline, but this is not the case. This decrease in VE that follows saline 
injection has always been observed. 
VE is defined as the volume of gas exhaled from a person's lungs in one minute. 
Positive VE mean percent changes are indicative of an increase in respiration, while 
negative VE changes are an indication that respiration is decreasing. In the present 
experiment, both DPCPX and CPT VE mean percent change values were higher at all 
dosages compared to the saline treated group (figs. 20, 21, & 23), suggesting that 
DPCPX & CPT increase respiration. Moreover, DPCPX VE mean percent change values 
suggest that it is not only a greater respiratory stimulant than CPT, but there is a dose-
response relationship ofDPCPX as well (figs 20, 21, 23 & Tables 1-4). The conclusion 
that DPCPX stimulates VE more than CPT is most recognizable at DPCPX 160 µg/kg 
(figs 20, 21, 23). 
Respiratory rate (t) is defined as the number of breaths taken per minute. In rela-
tion to saline treated newborn rats, f decreased shortly after saline treatment, resulting in 
~30% decrease from 5 min to the end of the 60 min recoding period (fig. 24). Both 
DPCPX and CPT f mean percent change values were higher at all dosages compared to 
the saline treated group (figs. 24, 25, & 27), suggesting that DPCPX & CPT both 
increase respiratory rate. DPCPX f mean percent change values analysis suggest that it is 
not only a greater respiratory stimulant than CPT, but there is a slight dose response rela-
tionship of DPCPX as well (figs. 24, 25, 27 & Tables 5-8). 
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VT is defined as the amount of air displaced between normal inspiration and nor-
mal expiration (the amount of air moved into and out of the lungs during normal breath-
ing). It can also be determined by taking volume of gas inhaled or exhaled from a per-
son's lungs in one minute divided by the number of breaths taken per minute (Vp/f). In 
saline-treated newborn rats, VT response was quite variable. At 25 min VT was increased 
by 28% and at 30 min it was decreased by 9% (fig. 28). The results concerning VT in 
terms of DPCPX and CPT treatments were also highly variable. DPCPX & CPT VT 
mean percent change values were not greater than the saline treated group. Moreover, for 
the most part DPCPX had lower or negligible VT mean percent change values compared 
to CPT (figs. 28, 29, 31). There is no dosage response relationship for either DPCPX or 
CPT. Nonetheless, a higher VT mean percent change value for one treatment does not 
necessarily mean it was a greater respiratory stimulant than the other treatment. This is 
because a high f compared to VE or a low VE compared to f could decrease VT. Moreo-
ver, if VE and fare both higher for one treatment compared to another treatment VT could 
still be lower, because VT mean percent change values solely depend upon the difference 
of VE from f. This is most likely the scenario (both high, f sand low VE most likely con-
tributed to the high variability of VT) when comparing DPCPX & CPT in terms of VT. 
MIF is defined as the average rate of airflow during inspiration. It is calculated as 
VT divided by the time of inspiration (T1). This is a measure of central respiratory drive 
(Rigatto et al. 1975). A higher MIF mean percent change value suggests that respiratory 
drive has increased, while a lower value suggests that respiratory drive is decreasing. In 
saline-treated newborn rats, MIF decreased shortly after injection. Saline caused a ~30-
40% decrease in MIF (fig. 32). Both DPCPX & CPT had higher MIF mean percent 
change values than the saline treated group (figs. 32, 33, 35 & Tables 9-12). DPCPX 
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MIF mean percent change values were higher at higher dosages (with the exception of 
640 µg/kg) compared to CPT (figs. 32, 33, & 35). However, in terms ofMIF, there is not 
a strong dose-response relationship for either DPCPX or CPT. 
This work along with other related studies, illustrates that using rats as potential 
models for neonatal apnea can provide powerful, reliable, and useable data. One of the 
important functions of the respiratory center is to regulate the respiratory response to 
C02, a powerful respiratory stimulant. The buildup of C02 in the blood is the reason you 
cannot hold your breath for long periods of time. The respiratory response to C02 in 
adults is to increase both VT and f, resulting in a significant increase in VE. In the study 
conducted by Rigatto et al. (1975) they looked at the respiratory response to C02 in 
premature infants and found that they increase VT, but not f, in response to inhaled C02. 
However, full-term infants increase both VT and fin response to C02, suggesting that 
maturation of the respiratory center around the time of birth results in a frequency 
response to C02 that isn't there in premature infants (Rigatto et al. 1975). Moreover, in 
another study conducted by Dr. McGilliard, it was found that 7-day-old rats increase VT 
in response to inhaled C02, but do not show an increase in frequency, just like the 
premature human infants. By the time the rats are 14 days old, they have a frequency 
response to C02, just like full-term infants (McGilliard 1984 ). 
Thus the similarities between neonatal rats and premature infants in terms of 
apnea (e.g. immature respiratory system, breathing patterns, adenosine receptors, 
pharmacological physiology and functions of methylxanthine derivatives etc.) allow for 
the potential of obtaining an efficient treatment strategy for neonatal apnea. Moreover, 
these variables are often used or comparable to other respiratory variables used in clinical 
settings. 
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Some may argue, that while this study showed that respiratory stimulation 
occurred as a result of the use of methylxanthine treatments, this does not necessarily 
mean ''just because you breathe faster you are getting more air". While this may be true 
in some instances, this study's method of analyzing respiratory stimulation illustrated the 
contrary by not only including parameters that measured the increase in volume of air 
(e.g. VE, f, VT), but by also charting this increase in air over time (fig. 19). 
The respiratory variables VE, f, VT, and MIF are best analyzed by examining the 
mean percent change in these variables. Mean percent changes were depicted as opposed 
to the raw data because it provides a more accurate illustration of treatment differences, 
as well as an overall generalized conclusion about the significance of the these different 
treatments. For instance, DPCPX VE mean percent change was on average higher at 
higher dosages compared to lower dosages suggesting that there is a dose-response 
relationship. Also DPCPX in terms of all the respiratory variables analyzed had higher 
mean percent changes than CPT. In general, drug-induced changes in VE, f, and MIF 
were quite similar, whereas VT results were quite variable and not statistically 
significant. 
Weight, gender, and age can often influence the severity of sleep apnea (Barnett 
et al. 2011, Young et al. 2009). Weight is obviously a factor affecting respiratory 
volumes. A larger rat will have larger lungs and greater VT and VE than a smaller rat. 
Each rat, was administered a standardized methylxanthine dosage based on its body 
weight (µg/kg), so the influence of weight was controlled for. Nonetheless, for example, 
when a DPCPX specific dosage range of methylxanthine rats on average has a higher 
weight than CPT at the same specific dosage it may play a factor in respiratory response. 
As shown in Table 13, although weight differed between DPCPX and CPT rats at similar 
86 
dosages it is not believed to have been a major factor in influencing respiratory 
stimulation. DPCPX rats had a higher average weight at 20, 40, 320, and 640 µg/kg 
compared to CPT rats, yet CPT exhibited both higher respiratory stimulation (e.g. VE at 
640 µg/kg) and lower respiratory stimulation (e.g. fat 320 µg/kg) compared to DPCPX 
at equivalent dosages. It should be noted that larger rats did have a higher baseline VT. 
One suggestion was to standardize each respiratory variable in terms of rat weight; (ex. 
ml/g body weight for adjusted VT)-however, since the major goal is to compare the 
effects of different doses of the 8-cyclopentylxanthines and each rat serves as its own 
control, % change accounts for variability between rats, which would also include 
variability due to size. More testing may be necessary to determine the degree to which 
weight plays a role in influencing respiratory stimulation. Gender was also not a 
noticeable factor influencing respiratory stimulation (Table 14). There was no correlation 
between gender and respiratory stimulation for any of the respiratory variables. Age is a 
factor in determining the degree of respiratory stimulation (Table 15) but only in the 
sense that the experiment involved 4-to-7 day old rats only. Seven-day-old rats are more 
mature and considerably larger than 4-day-old rats. Nonetheless, within this age range 
there was not a noticeable difference in respiratory stimulation for any of the respiratory 
variables. 
In concordance with previous studies (Schmidt et al. 2007, McGilliard et al. 1990, 
and McGilliard and Saeki 2002, Aranda et al. 1986, and Rigatto et al. 1975), this study 
illustrates that methylxanthines increase respiratory stimulation. Moreover, the degree to 
which this stimulation occurs is highly dependent not only on the physiology and 
anatomy (i.e. obstructive vs. central apnea, immature vs. mature respiratory system) of 
the CNS but also on adenosine and its receptors. Specifically, in neonatal apnea the 
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medulla of infants is often immature, and as a result often improperly or ineffectively 
modulates respiration (McGilliard 1984). In a study conducted by Herlenius et al. (1997), 
adenosine had been implicated in modulating activity by acting directly on brainstem 
respiration-related networks. Herlenius also suggested that theophylline and caffeine are 
adenosine antagonists that cause ventilation to increase by the antagonistic effect of these 
drugs on Ai-receptors in the medulla oblongata. 
Knowing this, it is now understandable that synthesizing xanthine analogs with 
more potent Ai receptor antagonism may, lead to increases in respiratory stimulation. 
DPCPX and CPT, which are both potent Ai receptor antagonists, exemplify 
this notion by increasing VE, f, and MIF in comparison to less potent Ai receptor 
antagonists, such as caffeine and theophylline. Moreover, DPCPX-a more potent Ai 
receptor antagonist than CPT, on a whole (Shamim et al. 1989)-exhibited greater 
respiratory stimulation. Nonetheless, while this study demonstrated that methylxanthines 
can be used to treat conditions similar to neonatal apnea, it is important to realize that 
there is inconclusive evidence regarding many of the potential long-term effects (e.g. 
development of brain and other organs, synthesis of cholesterol in cultured glial cells, 
seizures, anxiety, etc.) (Aranda et al. 1986, Schmidt et al. 2007). However, many of the 
previous studies involving methylxanthines as treatment for neonatal apnea concluded 
that the benefits outweigh any of the long-term potential risks (Aranda et al. 1986, 
Schmidt et al. 2007). 
Future studies involving methylxanthine treatment for neonatal apnea may be 
necessary to determine its exact efficacy. Synthesis of new xanthine analogs that are 
specific to the type and severity of apnea is also important. It has already been 
determined that with the proper model of experimentation, and by manipulating 
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xanthines and varying the dosage, methylxanthine treatment can be an effective treatment 
strategy for neonatal apnea. While the limit of solubility of these xanthine analogs was 
observed at a concentration of 64 µg/ml, preventing testing at higher doses, it would be 
interesting to see how these two drugs work in response to the presence of C02. 
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CHAPTER 6: CONCLUSION 
In conclusion, both DPCPX and CPT increase respiration in neonatal rats 
compared to saline control treatments. But unlike CPT, there was also a dose-response 
relationship between DPCPX treatment and respiratory stimulation suggesting that 
DPCPX was a more potent respiratory stimulant than CPT, presumably based on its 
higher affinity for A1 adenosine receptors. 
In saline-treated newborn rats, VE, f, and MIF decreased ~30-40 % after saline 
treatment. On the other hand saline-treated newborn rats did not show a steady decrease 
in VT. Instead, the results were quite variable. 
Time did not play a significant factor for either DPCPX or CPT (with the 
exception of CPT respiratory rate) treatments for any of the respiratory variables. 
DPCPX, in contrast to CPT, exhibited treatment x time interactions. DPCPX had 
significant treatment x time interactions for VE and MIF mean percent change. 
DPCPX illustrated some degree of a dosage-response relationship for the 
respiratory variables: VE, f, and MIF mean percent change. The dosage-response 
relationship seemed to be strongest for VE percent change while f, and MIF mean percent 
change had noticeable but slightly weaker dosage-response relationships. CPT did not 
demonstrate any type of dosage-response relationship in terms of VE, f, or MIF mean 
percent change. 
Overall, DPCPX exhibited greater respiratory stimulation in terms of VE, f, and 
MIF mean percent change compared to CPT. DPCPX at higher dosages (specifically in 
the range of 80-320 µg/kg) exhibited greater VE, f, and MIF mean percent change. This 
along with the fact that CPT shows no dosage-response relationship as predicted suggests 
that DPCPX is a more potent respiratory stimulator. 
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In relation to VT there was no statistical significance for% change in VT for either 
CPT or DPCPX. In fact VT for DPCPX and CPT was highly variable. Because of this it 
is impossible to state that CPT or DPCPX increases VT, nor was it possible to compare 
the two. In fact, the data concerning VT were so highly variable that it was difficult to 
find a trend toward a dose-response relationship with VT. 
This thesis examined the effectiveness of methylxanthine treatment on neonatal 
rats in terms of respiratory response, and how structurally manipulated methylxanthines 
can be used as treatment strategies for neonatal apnea. It accomplished this by comparing 
two potent A1 adenosine receptor antagonists (DPCPX and CPT) in terms of their 
respiratory response as well as to previous studies involving less potent adenosine 
receptor antagonists (i.e. caffeine, theophylline ), and compared the dosage-response 
relationship ofDPCPX and CPT in terms of respiratory response. This thesis also 
demonstrated that VE, f, VT, and MIF can be used as indicators of respiratory response 
and thus variables to evaluate the effectiveness of methylxanthine treatment. Moreover, it 
validated the overall effectiveness of this experimental design for future respiratory 
studies-specifically for the treatment of neonatal apnea. Lastly, this study provided a 
general understanding and awareness of sleep apnea and neonatal apnea. 
Finally, while there are many different suitable treatment strategies (i.e. surgery, 
prone positioning, CPAP therapy, etc.), they vary in the degree of efficacy for treating 
neonatal apnea. Methylxanthine treatment, albeit fairly new, may be one the best 
potential treatment strategies. This is due primarily to the fact that methylxanthine 
treatment not only has been demonstrated to be effective, but it also can be manipulated 
in a myriad of different ways (e.g. types, structures, dosages) that are best suitable to the 
particular circumstance (i.e. severe vs. mild apnea, adult vs. child, etc.). This study 
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directly demonstrates this and underlines the potential of methylxanthine treatment for 
neonatal rats. Moreover, Dr. Kip McGilliard's experimental paradigm for measuring 
respiratory stimulation in terms of VE, f, VT, and MIF using provides an effective method 
for evaluating the effectiveness of methylxanthine treatment. 
92 
REFERENCES 
Antonescu-Turcu A, Parthasarsathy S. CPAP and bi-level PAP therapy: New and 
established roles. Respir Care [Internet]. 2010 September [cited 2012 March 10] 
55(9):1216-1228. 
Apnea. The American Heritage Dictionary of the English Language [Internet]. Houghton 
Mifflin Company; [cited 2012 March 12] <http://www.thefreedictionary.com/apnea>. 
Aranda N, Laudignon N, Sasyniuk BI. Pharmacologic effects oftheophylline in the 
newborn. 1986. J of Allergy and Clin Immunol: 78; 773-780. 
Barnett M, Namen AM, Dunagan DP, Fleishcer A, Tillett J, McCall V, Haponik EF. 
Increased physician-reported sleep apnea. Chest J. [Internet]. 2002 [cited 2012 March 
10]:121 (6):1741-1748. <http://www.ebsco.com>. 
Beardsell I, Bell S, Rumbold H. MCEM Part A:MCQs, page 33, Royal Society of 
Medicine Press, 2009. 
Bhatia J. Current options in the management of apnea of prematurity. Clin Pediatr 
[Internet]. 2000 [cited 2012 March 12]: 39:327-336. <http://www.online.sagepub.com>. 
Bhatt-Mehta V, Schumacher ER. Treatment of apnea of prematurity. Pediatr Drugs 
[Internet]. 2003 [Cited 2012 March 15]: 5(3):195-210. 
Bozzetti V, Tagliabue P, Rhein L. 2010 [cited 2012April 2]. Evaluation ofhealthy full-
term and late premature infants presenting with apnea in the newborn nursery: A 
comparison of neonatal apnea and infantile acute life threatening event (ALTE). J of 
Neonatal-Perinatal Med. [Internet]:217-276. <http://www.ebsco.com>. 
Bradley DT. Respiratory sleep medicine. Am J Respir Crit Care Med. [Internet]. 2008 
[cited 2012 March 14]:177: 363-364. 
Bradley DT, Dai Y. Central sleep Apnea and cheyne-stokes respiration. Proc Am 
Thoracic Soc [Internet]. 2008 [cited 2012 March 12]: 5:226-236. 
<http://www.ebsco.com>. 
Brouillette TR, Weese-Mayer ED, Hunt EC. Breathing control disorders in infants and 
children. Hosp Prac. 1990 [cited 2012 March 13]. 
Brown LK, Gay PC, Gordon N, Morgenthaler TI. Adaptive servoventilation versus 
noninvasive positive pressure ventilation for central, mixed, and complex sleep apnea 
syndromes. Sleep [Internet]. 2007 [cited 2012 March 17]: 30(4): 468-475. 
Dempsey AJ, Veasay CS, Morgan JB, O'Donnell PC. Pathophysiology of sleep apnea. 
Physiol Rev. [Internet]. 2010 [cited 2012 March 15]. 
93 
Dhand R. Sleep disorders, diagnosis and treatment. J Respir Care. [Internet]. 2010 [cited 
2012 April 1] :55(10): 1389-1396. <http://www.ebsco.com>. 
Dorion D, Praud J-P. The larynx and neonatal apneas. Otolaryngology-Head and Neck 
Surg [Internet]. 2003 [cited 2012 April 2]: 128: 463-469. 
<http://www.online.sagepub.com>. 
Eltzschig KH. Adenosine: An old drug newly discovered. Anesth. [Internet]. 2009 
October [cited 2012 March 9]: 111(4): 904-915. 
Erler T, Paditz E. Obstructive sleep apnea syndrome in children. Treat Respir Med. 
[Internet]. 2004 [cited 2012 April 2]: 3(2): 107-122. 
Fredholm BB. Adenosine receptors as drug targets. Exp Cell Respir [Internet]. 2010 May 
1[cited2012 March 13]: 316(8): 1284-1288. 
Goessler UR, Hein G, Verste T, Stuck BA, Hormann K, Maurer JT. Soft palate implants 
as a minimally invasive treatment for mild to moderate obstructive sleep apnea. Acta 
Oto-Laryngol [Internet]. 2007 [cited 2012 March 30]: 127:527-531. 
Herlenius E, Lagercrantz H, Yamamoto Y. 1997. Adenosine modulates inspiratory neu-
rons and the respiratory pattern in the brainstem of neonatal rats. Pediatr Res. 
Hollenstein J. Sleep Apnea; Obstructive Apnea; Central Apnea; Mixed Apnea. Conditions 
and Procedures In Brief [Internet]. 2010 [cited 2012 March 25]. 
<http://www.ebsco.com>. 
Klaasse EC, IJzerman, AP, de Grip WJ, Beukers MW. Internalization and desensitization 
of adenosine receptors. Purinergic Signaling [Internet]. 2008 [cited 2011 July 16] :4: I: 
21-3 7. <http:/ !repository. ubn.ru.nl/handle/2066/69662>. 
Malhotra A, Owens RL. "What is central sleep apnea". Respir Care [Internet]. 2010 
[cited 2011July16]: 55.9:1168-1176. <http://www.ebsco.com>. 
McGilliard, K.L.1984. Biphasic alteration of the ventilatory response to C02 in newborn 
rats after chronic maternal hypercapnia. Physiologist 27.4: 234. 
McGilliard KL, Reynolds S, Gatto C. 1990. Effects of xanthine analogs on respiratory 
control in newborn rats. Abstracts, Modulation of Respiratory Pattern: Peripheral and 
Central Mechanisms, p. 79. 
Milic-Emili J, Grunstein MM. 1976. Drive and timing components of ventilation. Chest 
70, 131-133. 
Mount Nittany Health. How Breathing Works [Internet]. 2009 [Cited 2012 September 7]. 
http://www.mountnittany.org/articles/healthsheets/322. 
94 
"Obstructive Sleep Apnea". American Academy of Sleep Medicine [Internet]. 2008 
[Cited 2011 July 21]. <http://www.aamsnet.org>. 
Orozco-Gregorio H, Mota-Rojas D, Villanueva D, Bonilla-Jaime H, Suarez-Bonilla X, 
Torres-Gonzalez L, Bolanos D, Hernandez Gonzalez R, Martinez-Rodriguez R,Trujillo-
Ortega ME. Caffeine therapy for apnoea of prematurity: pharmacology treatment. Af J 
of Pharm and Pharmacol [Internet].2011 May [Cited 2012 2 April]: 5(4): 564-571. 
<http://www.academicjournals.org/ajpp>. 
Patil SP, Schneider H, Schwartz Ar, Smith PL. Adult obstructive sleep apnea: 
pathophysiology and diagnosis. Chest J. [Internet]. 2007 January [cited 2012 March 10]: 
132: 325-337. <http://www.chestjournal.chestpubs.org>. 
Persson CGA. Xanthines for asthma-present status. Trends Pharmacol Sci 1982. 3: 312-
313. 
Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998 
[cited 2012 March 18]: 50(3): 413-492. 
Rall T. Drugs used in the treatment of asthma. The Pharmacology Basis of Therapeutics. 
1990 [Cited 2012 September 7]: 618-630. 
Rigatto H, Brady JP, de la Torre Verduzco R. Chemoreceptor reflexes in preterm infants 
II. The effect of gestational and postnatal age on the ventilatory response to inhaled 
carbon dioxide. Pediatr [Internet] 1975 [Cited 2012 September 7]: 55: 614-620. 
Roux F, D'Ambrosio C, Mohsenin V. Sleep-related breathing disorders and 
cardiovascular disease. Arn J Med. [Internet]. 2000 April 1 [cited 2012 March 31]:108: 
396-402. 
Saeki Y, McGilliard KL. 2002. Effect of caffeine on the ventilatory response to C02 in 
newborn rats. Abstracts, 13th Annual Student Research Conference, p. 39. 
Schmidt B, Roberts SR, Davis P, Doyle WL, Barrington JK, Ohlsson A, Solirnano A, Tin 
W. Caffeine therapy for apnea of prematurity. N Eng J Med. 2006. 354; 2112-2112. 
Schmidt B, Roberts SR, Davis P, Doyle WL, Barrington JK, Ohlsson A, Solirnano A, Tin 
W. Long-term effects of caffeine therapy for apnea of prematurity. N Eng J Med. 2007. 
357; 1893-1902. 
Shamirn TM, Ukena D, Padgett LW, Daly W J. Effects of 8-phenyl and 8-cycloalkyl 
substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with 
substitution at the 1-, 3-, and 7-positions. J Med Chern. 1989 [Cited 2012 March 13]: 32: 
1231-1237. 
Sigma-Aldrich Corporation, 2012. <http://www.sigmaaldrich.com/united-states.html>. 
Van Calker, D., Muller, M. and Hamprecht, B. (1979). J. Neurochern. 33:999-1005. 
95 
Voet D, Voet J, Pratt C. The major pathways of purine catabolism in animals, 
Fundamentals of Biochemistry: Life at the Molecular Level, 2008. p. 840. 
Young T, Palta M, Dempsey J, Peppard EP, Nieto FJ, Hla KM. Burden of sleep apnea: 
rationale, design, and major findings of the Wisconsin sleep cohort study. WMJ 
[Internet]. 2009 August [cited 2012 March 31]: 108(5): 246-249. 
Zhao J, Gonzalez F, Dezhi M. Apnea of prematurity: from cause to treatment. Eur J 
Pediatr [Internet]. 2011February8 [cited 2012 March 15]. 
96 
APPENDIX I: Description of Respiratory Elements 
A. Minute Ventilation (VE): Minute Ventilation (VE) (also referred to as respiratory 
minute volume) measured in ml/min is defined as the volume of gas exhaled from a 
person's lungs in one minute. VE represents a change in volume over time. It can be 
measured directly or calculated from other respiratory parameters. If tidal volume (VT) 
and respiratory rate (f) are known, VE can be calculated by multiplying VT& f. In other 
words VE= VTX f. In addition, VE= (VT/Tr) x (Tr/TmT) (however dead space needs to be 
taken into account) (Milic-Emili 1976). 
B. Respiratory Rate (t): Respiratory rate (f) measured in breaths/minis defined as the 
number of breaths taken per minute. 
C. Tidal Volume (VT): Tidal Volume (VT) measured in ml is defined as the amount of air 
displaced between normal inspiration and normal expiration or simply the amount of air 
moved into and out of the lungs during normal breathing (Beardsell et al. 2009). VT=V&f 
D. Time of Expiration (TE): Time of Expiration (TE) measured in sec is defined as the 
amount of time (duration) of each expiration. It can be calculated as the total time of each 
breath subtracted by the time of inspiration. TE= T TOT-T1 
E. Time of Inspiration (T1): Time of Inspiration (Ti) measured in sec is defined as the 
amount of time (duration) of each inspiration. 
F. Mean Inspiratory Flow (MIF): Mean Inspiratory Flow (MIF) is the average rate of 
air flow during inspiration. It is measured in ml/sec and is calculated as the amount of air 
displaced during normal inspiration divided by the time of inspiration. MIF= VT/Tr 
G. Total Time of Each Breath (TToT): The Total Time of Each Breath (TmT) is 
measured in seconds and is the sum of TE and Tr. It is calculated as the reciprocal of 
respiratory rate (f) x 60. TTOT=TE+ T1 and TmFllf x60 
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APPENDIX II: Statistical Tables 
Table 1: CPT Minute Ventilation VE Treatment vs. Saline. Two-Way Repeated 
Measures AN OVA (One Factor Repetition). 
CPT Minute Ventilation (VE) 
Treatment CPTlO CPT20 CPT40 CPT80 CPT 160 CPT320 CPT640 
vs. Saline P=0.002 P=0.001 
Table 2: CPT Minute Ventilation VE Treatment x Time Interaction Pairwise 
Multiple Comparison Procedure (Holm-Sidak Method: p=<0.05). 
CPT Minute Ventilation (VE) 
Treatment x CPTlO CPT20 CPT40 CPT80 CPT 160 CPT320 CPT640 
Time 
5 min 
10 min 
15 min P=0.013 P=0.033 
20 min P=0.020 
25 min P=0.012 P=0.003 
30 min P=0.011 P<0.001 
35min P=0.006 P<0.001 
40min P<0.001 P=0.032 P=0.026 P<0.001 
45 min P=0.005 P=0.021 
50 min P<0.001 P=0.008 
55 min P=0.001 P=0.005 
60min P<0.001 P=0.021 P<0.001 
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Table 3: DPCPX Minute Ventilation VE Treatment vs. Saline. Two-Way Repeated 
Measures ANOVA (One Factor Repetition). 
DPCPX Minute Ventilation (VE) 
Treatment DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX 
10 20 40 80 160 320 640 
Vs. Saline P<0.001 P<0.001 P=0.001 
Table 4: DPCPX Minute Ventilation VE Treatment x Time Interaction. Pairwise 
Multiple Comparison Procedure (Holm-Sidak Method: p=<0.05). 
DPCPX Minute Ventilation (VE) 
Treatment x DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX 
Time 10 20 40 80 160 320 640 
5 min 
P=0.040 
lOmin 
15 min P=0.023 
20 min P=0.003 P=0.025 
25min P<0.001 P=0.046 P=0.038 
30min P<0.001 P=0.006 P=0.003 
35 min P<0.001 P=0.021 P=0.004 
40min P<0.001 P=0.026 P=0.001 
45 min P=0.001 P=0.008 P=0.012 
50min P<0.001 P=0.002 P=0.002 
55 min P=0.007 P=0.002 P=0.006 
60 min P<0.001 P<0.001 P=0.025 
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Table 5: CPT Respiratory Rate f Treatment vs. Saline. Two-Way Repeated 
Measures AN OVA (One Factor Repetition). 
CPT Respiration (t) 
Treatment CPTlO CPT20 CPT40 CPT80 CPT 160 CPT320 CPT640 
Vs. Saline P=0.019 P=<0.001 
Table 6: CPT Respiratory Rate f Treatment x Time Interaction. Pairwise Multiple 
Comparison Procedure (Holm-Sidak Method: p=<0.05). 
CPT Respiration (t) 
Treatment x CPTlO CPT20 CPT40 CPT80 CPT CPT CPT640 
Time 160 320 
5 min 
lOmin P=0.045 
15 min P=0.046 P=0.015 
20min P=0.027 P=0.010 
25 min P=0.036 P=0.032 P=0.017 P=0.005 P<0.001 P=0.013 
30min 
35min 
40min P=0.011 P<0.001 
45 min P=0.005 
50min P=0.004 
55 min P=0.007 
60min P=0.050 P=0.010 P=0.033 P=0.034 P<0.001 
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Table 7: DPCPX Respiratory Rate fTreatment vs. Saline.1\vo-Way Repeated 
Measures ANOVA (One Factor Repetition). 
DPCPX Respiration (t) 
Treatment DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX 
10 20 40 80 160 320 640 
Vs. Saline P=0.024 P<0.001 P=0.001 P=0.002 
Table 8: DPCPX Respiratory Rate f Treatment x Time Interaction. Pairwise 
Multiple Comparison Procedure (Holm-Sidak Method: p=<0.05). 
DPCPX Respiration (t) 
Treatment x DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX 
Time 10 20 40 80 160 320 640 
5 min 
10min 
15min P<0.001 
20min P=0.012 
25min P=0.040 P<0.001 P<0.004 P=0.014 
30min P=0.045 P<0.003 P=0.014 
35min P<0.003 
40min P=0.005 P=0.022 P=0.043 
45min P<0.001 P=0.037 
50min P=0.050 P<0.001 P=0.013 
55min P<0.001 P=0.011 
60min P=0.005 P=0.031 
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Table 9: CPT Mean Inspiratory Flow MIF Treatment vs. Saline. Two-Way Repeated 
Measures ANOVA (One Factor Repetition). 
CPT Mean Inspiratory Flow (MIF) 
Treatment CPTlO CPT20 CPT40 CPT80 CPT 160 CPT320 CPT640 
Vs. Saline P=0.029 P<0.001 P=0.032 P=0.034 P=0.025 P<0.001 
Table 10: CPT Mean Inspiratory Flow Treatment x Time Interaction. Pairwise 
Multiple Comparison Procedure (Holm-Sidak Method: p=<0.05). 
CPT Mean Inspiratory Flow (MIF) 
Treatment x CPTlO CPT20 CPT40 CPT80 CPT CPT CPT640 
Time 160 320 
5 min P=0.039 
tomin 
15 min P<0.001 P=0.012 
20min P=0.029 P=0.007 
25min P=0.001 P=0.001 
30min P=0.030 P<0.001 P=0.034 P=0.045 P=0.015 P<0.001 
35min P=0.001 P<0.001 
40min P=0.024 P<0.001 P=0.021 P=0.033 P=0.018 P<0.001 
45min P<0.001 P=0.017 
50min P=0.011 P<0.001 P=0.015 P=0.018 P=0.015 P=0.006 
55min P<0.001 P=0.019 
60min P=0.014 P<0.001 P=0.016 P=0.021 P=0.029 P<0.001 
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Table 11: DPCPX Mean Inspiratory Flow MIF Treatment x Saline. Two-Way 
Repeated Measures ANOVA (One Factor Repetition). 
DPCPX Mean Inspiratory Flow (MIF) 
Treatment DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX 
10 20 40 80 160 320 640 
Vs. Saline P<0.001 P=0.041 
Table 12: DPCPX Mean Inspiratory Flow MIF Treatment x Time Interaction. Pairwise 
Multiple Comparison Procedure (Holm-Sidak Method: p=<0.05). 
DPCPX Mean Inspiratory Flow (MIF) 
Treatmentx DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX DPCPX 
Time 10 20 40 80 160 320 640 
5 min 
lOmin 
15 min 
20min P=0.002 
25min P<0.001 
30min P<0.001 P=0.039 
35min P=0.003 
40min P<0.001 
45min P<0.001 
50min P=0.012 P<0.001 P=0.017 P=0.042 
55min P=0.015 
60min P=0.001 P=0.013 
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Table 13: Average Weight (g) of Rats per Treatment per Dosage. 
Treatment Average Weight (g) 
Saline 15.36 
CPT 10 µg/kg 16.3 
CPT 20 µg/kg 13.82 
CPT 40 µg/kg 14.36 
CPT 80 µg /kg 13.89 
CPT 160 µg /kg 14.94 
CPT 320 µg /kg 11.73 
CPT 640 µg /kg 14.32 
DPCPX 10 µg /kg 13.24 
DPCPX 20 µg /kg 16.27 
DPCPX 40 µg /kg 16.9 
DPCPX 80 µg /kg 12.77 
DPCPX 160 µg /kg 12.88 
DPCPX 320 µg /kg 14.88 
DPCPX 640 µg /kg 18.93 
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Table 14: Gender Ratio of Rats per Treatment per Dosage 
Treatment Gender Ratio 
Saline 3 Male : 5 Female 
CPT 10 µg/kg 5 Male : 3 Female 
CPT 20 µg/kg 2 Male : 6 Female 
CPT 40 µg/kg 4 Male : 4 Female 
CPT 80 µg /kg 5 Male : 3 Female 
CPT 160 µg /kg 5 Male : 3 Female 
CPT 320 µg /kg 3 Male: 5 Female 
CPT 640 µg /kg 3 Male : 5 Female 
DPCPX 10 µg /kg 3 Male: 5 Female 
DPCPX 20 µg /kg 4 Male : 5 Fem ale 
DPCPX 40 µg /kg 3 Male : 5 Female 
DPCPX 80 µg /kg 2 Male: 6 Female 
DPCPX 160 µg /kg 3 Male : 5 Female 
DPCPX 320 µg /kg 4 Male: 4 Female 
DPCPX 640 µg /kg 6 Male: 2 Female 
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Table 15: Average Age (days) of Rats per Treatment per Dosage. 
Treatment Average Age (days) 
Saline 2(5 days) 2(6 days) 4(7 days) ; 6.25 
CPT 10 µ,g/kg 2(5 days) 4(6 days) 2(7 days) ; 6.00 
CPT 20 µ,g/kg 5(5 days) 2(6 days) 1(7 day) ; 5.50 
CPT 40 µ,g /kg 4(5 days) 4(6 days) ; 5.50 
CPT 80 µ,g /kg 1(5 day) 7(6 days) ; 5.88 
CPT 160 µ,g /kg 5(5 days) 1(6 day) 2(7 days) ; 5.63 
CPT 320 µ,g /kg 5(4 days) 1(5 day) 2(6 days) ; 4.63 
CPT 640 µ,g /kg 4(4 days) 2(5 days) 2(7 days) ; 5.00 
DPCPX 10 µ,g /kg 1(4 day) 3(5/6 days) 1(7 day) ; 5.50 
DPCPX 20 µ,g /kg 5(6 days) 3(7 days) ; 6.38 
DPCPX 40 µ,g /kg 4(6 days) 4(7 days) ; 6.50 
DPCPX 80 µ,g /kg 8(6 days) ; 6.00 
DPCPX 160 µ,g /kg 6(5 days) 2(6 days) ; 5.25 
DPCPX 320 µ,g /kg 2(4/5 days) 3(6 days) 1(7 day); 5.38 
DPCPX 640 µ,g /kg 2(4 days) 1(6 day) 5(7 days) ; 6.13 
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